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Validation of the Functional Assessment of Cancer Therapy Cognitive Scale  
with Bone Marrow Transplant Patients 
 
Sheri R. Jacobs 
 
ABSTRACT 
 
Research has demonstrated that cancer patients report problems with cognitive 
functioning related to their cancer and their cancer treatments.  Cognitive complaints 
refer to subjective reports of problems such as decreased memory, attention, 
concentration, and language skills.  These problems with cognitive functioning can 
interfere with a person’s quality of life.  The current measures of cognitive complaints 
have poor or unknown psychometric properties.  Therefore, the present study sought to 
examine the psychometric properties of a newly developed measure of cognitive 
complaints for cancer patients, the Functional Assessment of Cancer Therapy Cognitive 
Scale (FACT-Cog).  Eighty-two patients were administered a comprehensive battery of 
neuropsychological tests assessing memory, executive functioning, motor, and attention, 
as well as a battery of psychosocial measures six months or twelve months after receiving 
a bone marrow transplant.  Results indicated that the internal consistency reliability of the 
FACT-Cog was high.  Concurrent validity was evidenced by the significant relationship 
of the FACT-Cog to another measure of cognitive complaints.  Convergent validity is 
evidenced by the significant relationship of the FACT-Cog to measures of depression, 
fatigue, anxiety, mental well-being, and physical well-being.  Divergent validity was 
evidenced by the lack of significant relationship of the FACT-Cog to a measure of 
extroversion.  In contrast, there was limited support for the criterion validity of the 
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FACT-Cog as evidenced by the limited significant relationships with neuropsychological 
test scores.  The FACT-Cog did not demonstrate superior psychometric properties to an 
existing measure of cognitive complaints (EORTC-CF).  Future research should 
investigate the relationship of cognitive complaints to cognitive performance utilizing 
longitudinal designs, other clinical populations, and neuropsychological tests that require 
sustained effort. 
 
 
 
 
  1
Introduction 
 Cognitive functioning among adult cancer patients has received increasing 
attention in recent years.  Research suggests that problems with cognitive functioning 
have a large impact on quality life, interfere with the ability to function in daily 
activities, and affect educational and career choices.  Therefore, it is important to 
correctly identify and assess problems associated with cognitive functioning.  Cognitive 
functioning has been assessed in two ways: by measuring cognitive performance on 
standardized neuropsychological tests and by obtaining self-reports of cognitive 
complaints.  Although methodology for assessing cognitive performance is fairly well 
developed, the same cannot be said for the assessment of cognitive complaints.  Current 
methods for measuring cognitive complaints either lack sound psychometric properties 
or have unknown psychometric properties.  Recognizing the need for a reliable and valid 
measure, Wagner, Sweet, Cella, and Doninger (2002) have developed the Functional 
Assessment of Cancer Therapy Cognitive Scale (FACT-Cog).  This measure of 
cognitive complaints is composed of behaviorally-based items in an effort to minimize 
the impact of distress unrelated to cognitive abilities.  The aim of the present study was 
to examine the psychometric properties of this newly developed instrument using bone 
marrow transplantation (BMT) patients as the validation sample. 
The following section will evaluate different methods of measuring cognitive 
functioning in cancer patients.  First, studies assessing cognitive complaints but not 
cognitive performance in cancer patients will be discussed.  Next, studies assessing both 
cognitive complaints and cognitive performance will be reviewed.  Finally, the 
development and structure of the FACT-Cog will be discussed. 
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Review of Cognitive Complaints Literature 
Although there is no consensus, cognitive complaints typically refers to subjective 
difficulties with memory, attention, concentration, and language skills (Olin, 2001).  
Cognitive complaints, such as difficulties with attention and concentration, may overlap 
with symptoms of depression and fatigue.  However, unlike depression and fatigue, 
cognitive complaints can include problems with mental acuity, verbal and nonverbal 
memory, verbal fluency, and the impact of decreased cognitive abilities on a person’s 
functioning and quality of life.  Although there is overlap among depression, fatigue, and 
cognitive complaints it is possible to distinguish them, and anecdotally patients report 
cognitive complaints without experiencing depression or fatigue.  This highlights the 
importance of reliably and validly measuring cognitive complaints.   
A variety of methods have been used to assess cognitive functioning in cancer 
survivors.  Some studies have relied on subjective measures to assess cognitive 
complaints without using objective measures of cognitive performance.  Five such studies 
can be identified.  Two studies used the Sickness Impact Profile (SIP) Alertness Behavior 
Scale (Bergner, Bobbitt, Carter, & Gilson, 1981) and the Profile of Mood State (POMS) 
Confusion Scale (McNair, Lorr, & Droppleman, 1971) and three studies used the 
European Organization for Research and Treatment of Cancer – Quality of life 
Questionaire-C30 Cognitive Functioning Scale (EORTC-CF; Aaronson, Ahmedzai, 
Bergman, Bullinger, & Cull, 1993) to assess cognitive complaints.   
The first study, by Andrykowski, Henslee, and Barnett (1989), used the SIP 
Alertness Behavior Scale and the POMS Confusion Scale to assess cognitive complaints.  
The SIP Alertness Behavior Scale consists of ten items assessing the presence of 
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difficulties in memory, attention, and concentration.  Higher scores indicate greater 
dysfunction.  The POMS Confusion Scale consists of seven descriptors, such as, 
‘confused’, ‘unable to concentrate’, ‘muddled’, and ‘efficient’.  Respondents indicate for 
the last week the degree to which each descriptor is characteristic of them.  Higher scores 
indicate greater dysfunction.  In this study, 16 allogeneic BMT patients were assessed 
two years following transplant and then again at four years post-transplant.  Scores on the 
SIP Alertness Behavior Scale improved significantly from time one to time two.  Scores 
at both assessments reflected more impairment in comparison to scores from a sample of 
renal implant patients and scores from a sample of chronic peritoneal dialysis patients.  
Scores on the POMS Confusion Scale remained stable across time and were similar to 
scores from the comparison samples.   
 A second study by Andrykowski et al. (1990) also assessed cognitive complaints 
using the SIP Alertness Behavior Scale and the POMS Confusion Scale.  Thirty 
allogeneic BMT patients were divided into three groups based on the amount of Total 
Body Irradiation (TBI) they had received: patients who received 900 cGy or less (N=13), 
patients who received 1200 cGy (N=9), and patients who received 1320 or 1400 cGy 
(N=8).  After controlling for age, time post-BMT, education, and current psychological 
distress, the SIP Alertness Behavior Scale was found to be significantly positively related 
to TBI dose.  The correlation between the POMS Confusion Scale and TBI dose only 
approached significance.   
Joly et al. (1998) used the EORTC-CF to assess cognitive complaints.  The 
EORTC-CF consists of two items rated on a four-point scale (1=Not at all, 2=A little, 
3=Quite a bit, 4=Very much).  One item assesses difficulty with concentration and the 
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other item assesses difficulty with memory.  The sample in this study consisted of men 
with localized prostate cancer (N=71) and healthy controls (N=71).  The prostate cancer 
patients were tested an average of four years post-treatment.  No significant difference 
was found on the EORTC-CF between patients and controls.   
Hjermstad, Holte, Evensen, Fayers, and Kaasa (1999) also administered the 
EORTC-CF to measure cognitive complaints.  The samples of cancer patients consisted 
of leukemia patients treated with high-dose chemotherapy and allogeneic BMT (N=41), 
lymphoma patients treated with high-dose chemotherapy and autologous BMT (N=51), 
and lymphoma patients treated with combination chemotherapy (N=85).  Lymphoma 
patients who underwent autologous BMT reported significantly greater cognitive 
complaints than the other two cancer groups and the healthy controls.  No significant 
differences existed between the leukemia patients treated with allogeneic BMT, the 
lymphoma patients treated with combination chemotherapy or the healthy controls.   
 Green, Pakenham, Headley, and Gardiner (2002) used the EORTC-CF to measure 
cognitive complaints in 65 prostate cancer patients at baseline and 6 months post-
treatment and 16 healthy controls over a similar time interval.  As part of their cancer 
treatment, prostate cancer patients were randomized to an observation group or a 
hormonal therapy group.  There was no significant difference in EORTC-CF scores 
between the observation group and the hormonal therapy group.  There was also no 
significant change in scores from time one to time two in either group.  As predicted, 
higher threat appraisal at baseline was significantly correlated with greater cognitive 
complaints at baseline and at 6 months.  Contrary to the authors’ prediction that greater 
use of emotion or problem-focused coping would be correlated with lower levels of 
  5
cognitive complaints, greater use of coping at baseline was significantly correlated with 
higher levels of cognitive complaints at 6 months.    
 In summary, evaluation of group differences provides limited support for the 
validity of the cognitive complaint measures.  Findings indicating that, as TBI dose for 
allogeneic BMT patients increased, scores of the SIP Alertness Behavior Scale also 
increased (Andrykowski et al., 1990) would be expected and, therefore, support the 
validity of the SIP Alertness Behavior Scale.  However, findings indicating that scores on 
the SIP Alertness Behavior Scale worsened significantly for allogeneic BMT patients 
from two years post-transplant to four years post-transplant (Andrykowski et al., 1989) 
are contrary to what would be expected.  Therefore, this finding does not support the 
validity of the SIP Alertness Behavior Scale. 
Findings indicating that the correlation between the POMS Confusion Scale and 
TBI dose approached significance (Andrykowski et al., 1990) would be expected and 
provide partial support for the validity of the POMS Confusion Scale.  However, findings 
indicating that scores on the POMS Confusion Scale were stable over time from two 
years post-transplant to four years post-transplant (Andrykowski et al., 1989) are not 
what would be expected.  Rather, it would be expected that scores would decrease from 
two years to four years post-transplant.  This finding does not support the validity of the 
POMS Confusion Scale. 
Evidence regarding the validity of the EORTC-CF is also mixed.  Findings 
indicating that lymphoma patients treated with autologous BMT scored significantly 
higher on the EORTC-CF than lymphoma patients treated with combination 
chemotherapy and a group of healthy controls (Hjermstad et al., 1999) would be expected 
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and, therefore, support the validity of the EORTC-CF.  However in the same study, 
autologous BMT patients reported greater cognitive complaints on the EORTC-CF than 
allogeneic BMT patients (Hjermstad et al., 1999).  This finding is contrary to what would 
be expected given the better outcomes usually associated with autologous BMT than 
allogeneic BMT and, therefore, does not support the validity of the EORTC-CF.  Also in 
the same study, EORTC-CF scores were not significantly different for leukemia patients 
treated with allogeneic BMT, lymphoma patients treated with combination 
chemotherapy, and a group of healthy controls (Hjermstad et al., 1999).  This finding 
does not support the validity of the EORTC-CF because group differences would be 
expected between the different treatment groups and the healthy controls.  In another 
study, EORTC-CF scores were not different for localized prostate cancer patients and 
healthy controls (Joly et al., 1998).  Again, it would be expected that prostate cancer 
patients would score higher on the EORTC-CF than healthy controls and, therefore, the 
validity of the EORTC-CF is not supported.  No significant differences in EORTC-CF 
scores were found between prostate cancer patients receiving hormonal therapy and 
prostate cancer patients not receiving hormonal therapy (Green et al., 2002).  Group 
differences would be expected, with prostate cancer patients receiving hormonal therapy 
reporting greater cognitive complaints than prostate cancer patients not receiving 
hormonal therapy.  Therefore, this finding does not provide support for the validity of the 
EORTC-CF.  
Other findings reported in these studies also provide mixed evidence regarding 
the validity of the cognitive complaint measures.  Two studies (Andrykowski et al., 1989, 
1990) used two measures of cognitive complaints, the SIP Alertness Behavior Scale and 
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the POMS Confusion scale.  The SIP Alertness Behavior Scale was positively correlated 
with TBI dose and the POMS Confusion Scale approached significance with TBI dose 
(Andrykowski et al., 1990), providing partial support for the concurrent validity of the 
two measures.  The correlation between the SIP Alertness Behavior Scale and the POMS 
Confusion Scale was not reported.  Concurrent validity was not supported in another 
study (Andrykowski et al., 1989), in which the SIP Alertness Behavior Scale detected 
change over time, while the POMS Confusion Scale remained stable over time.  Again, 
the correlation between the SIP Alertness Behavior Scale and the POMS Confusion Scale 
was not reported.  In the three studies which used the EORCT-CF (Green et al., 2002; 
Hjermstad et al., 1999; Joly et al., 1998), no other measure of cognitive complaints was 
used, therefore, concurrent validity is unknown.   
Convergent validity was not demonstrated in any of the five previously mentioned 
studies (Andrykowski et al., 1989, 1990; Green et al., 2002; Hjermstad et al., 1999; Joly 
et al., 1998), as none of the cognitive complaint measures were compared to measures of 
constructs such as depression, fatigue, anxiety, and health-related quality of life.  One 
study (Green et al., 2002) did look at cognitive complaints, measured by the EORTC-CF, 
in relation to threat appraisal and coping.  As hypothesized by Green et al. (2002), greater 
threat appraisal was associated with more cognitive complaints.  However, contrary to 
expectations, greater not lesser use, of coping was correlated with higher cognitive 
complaints.   
As none of these studies used neuropsychological tests, criterion validity was not 
examined.  Also, none of the studies reported internal consistency for the scales.  As the 
EORTC-CF consists of only two items, internal consistency may be poor. 
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Review of Cognitive Complaints and Cognitive Functioning Literature 
In contrast to the studies described previously that assessed only subjective 
complaints, eight studies can be identified that used a measure of cognitive complaints as 
well as a neuropsychological test battery to assess cognitive functioning.  To measure 
cognitive complaints, one study used the Medical Outcomes Study (MOS) Cognitive 
Functioning Scale (Stewart & Ware, 1992), one study used the Squire Memory Self-
Rating Questionnaire (Squire, Wetzel, & Slater, 1979), one study used the Concentration 
scale of the Checklist Individual Strength (CIS), the Alertness and Intellectual scales of 
the SIP, and daily complaints of memory and concentration (Vercoulen et al., 1994), and 
five studies used the EORTC-CF.  Of the five studies that used the EORTC-CF, three 
also used a checklist of cognitive problems in daily life, and one also used an interview-
based rating by a neuropsychologist to assess cognitive complaints. 
Klein et al. (2002) used the Cognitive Functioning Scale of the MOS to assess 
cognitive complaints.  The MOS Cognitive Functioning Scale consists of six items 
adapted from the SIP that assess confusion, concentration and thinking, attention, 
memory, reasoning, and psychomotor function.  Each question is rated on a six-point 
Likert-type scale (1=All of the time, 2=Most of the time, 3=A good bit of the time, 
4=Some of the time, 5=A little of the time, 6=None of the time).  The study sample 
consisted of patients with glioma who had been treated with radiotherapy (N=104), 
patients with glioma who had not been treated with radiotherapy (N=91), and patients 
with hematological cancer (N=100).  Neuropsychological measures tested the domains of 
intelligence, perception and psychomotor speed, attention and executive function, and 
memory.  Glioma patients treated with radiotherapy and without radiotherapy reported 
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significantly lower scores on the MOS Cognitive Functioning Scale than published data 
on healthy controls, but did not differ from patients with hematological cancer.  No 
difference was found on the MOS Cognitive Functioning Scale between glioma patients 
treated with or without radiotherapy.  Among glioma patients, scores on measures of 
memory, attention, psychomotor speed, and graphomotor speed were moderately 
correlated with cognitive complaints (r = .23, .30, 34, and .31, respectively). 
Ahles et al. (2002) used the Squire Memory Self-Rating Questionnaire to measure 
cognitive complaints in cancer patients five years post-treatment.  The Squire Memory 
Self-Rating Questionnaire consists of 18-items rated on a nine-point scale ranging from –
4 (worse than ever before) to +4 (better than ever before).  Each item inquires about a 
different aspect of memory functioning and was derived from remarks the scale 
developers obtained from patients treated with electroconvulsive therapy.  The sample in 
this study consisted of breast cancer patients treated with chemotherapy (N=35), 
lymphoma patients treated with chemotherapy (N=36), breast cancer patients treated with 
local therapy (N=35), and lymphoma patients treated with local therapy (N=22).  Each 
patient was administered neuropsychological tests assessing verbal ability, spatial ability, 
verbal learning, verbal memory, visual memory, psychomotor function, motor 
functioning, attention, and attention reaction time.  Factor analysis of the Squire Memory 
Self-Rating Questionnaire yielded three factors: new learning, working memory, and 
remote retrieval.  The factor of working memory was found to be significantly lower for 
patients treated with chemotherapy than local therapy.  The correlation between the 
factors and the neuropsychological domains were described as generally low and 
nonsignificant (values not reported). 
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Servaes, Verhagen, and Bleinjenberg (2002) used three instruments to assess 
cognitive complaints: the Concentration scale of the CIS, the Alertness and Intellectual 
scales of the SIP, and a daily record of complaints about memory and concentration.  The 
CIS Concentration scale consists of five items scored on a seven-point Likert scale with 
higher scores indicating a higher level of concentration problems.  To determine daily 
complaints of memory and concentration, patients were asked to keep a self-observation 
list for a 12-day period.  Memory and concentration problems were rated four times daily 
(0=No, 1=Yes).  Total daily scores ranged from 0 to 4, with high scores indicating more 
problems with memory and concentration.  The sample consisted of 150 breast cancer 
patients who were divided into two groups, severely fatigued patients (n=57) and 
nonseverely fatigued patients (n=93).  Patients were defined as severely fatigued if they 
scored 35 or higher on the Fatigue Severity Scale of the CIS.  Data were also collected 
for a control group of 78 friends and family of the breast cancer patients with no history 
of cancer.  Patients were tested six months to five years post-treatment.  The treatments 
patients received consisted of radiotherapy and chemotherapy (N=66), no chemotherapy 
or radiotherapy (N=20), chemotherapy only (N=33), or radiotherapy only (N=31).  
Neuropsychological tests assessed reaction time and concentration.  With one exception, 
severely fatigued breast cancer patients reported significantly more problems on all three 
measures of cognitive complaints than the nonseverely fatigued breast cancer patients 
and controls.  The exception was for daily reports of memory problems, in which no 
difference was seen between severely and nonseverely fatigued patients.  Nonseverely 
fatigued patients did not differ from controls on any measure of cognitive complaints.  
No significant differences in cognitive complaints existed between the different treatment 
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groups.  Severely fatigued, nonseverely fatigued, and controls did not differ on 
neuropsychological tests of concentration.  However, for reaction time, group differences 
did exist.  Severely fatigued patients were significantly slower compared to controls, but 
severely fatigued patients were not significantly different than nonseverely fatigued 
patients.  Nonseverely fatigued patients had slower reaction times than the controls for 
one of the three reaction time subtests.  The lack of differences between severely fatigued 
patients and nonseverely fatigued patients on a concentration task and a reaction time 
task are not consistent with the subjective reports, where severely fatigued patients had 
greater complaints than the nonseverely fatigued patients.   
Cull, Hay, Love, Mackie, Smets, and Stewart (1996) used the EORTC-CF to 
measure cognitive complaints in 91 lymphoma patients six months post-treatment.  The 
EORTC-CF was used to divide the sample into complainers (N=25) and non-complainers 
(N=66), which was defined as rating either question a “3” or a “4”.  Neuropsychological 
measures were used to test intelligence, concentration, and memory.  Complainers and 
non-complainers did not differ significantly on the neuropsychological measures of 
intelligence, memory, and concentration.  No significant difference was found between 
complainers and non-complainers on ratings of their health and global quality of life, 
however, complainers had significantly higher scores on measures of anxiety, depression, 
and fatigue than non-complainers.   
Van Dam et al. (1998) used the EORTC-CF and a checklist of cognitive 
complaints in daily life to measure cognitive complaints.  The checklist consisted of four 
questions assessing concentration, memory, thinking, and language.  Patients were asked 
to indicate the extent to which problems in each of these four domains occurred in their 
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daily life on a five-point Likert scale (0=Not at all, 1=Slightly, 2=Moderately, 3=Quite a 
bit, 4=Extremely).  The sample consisted of 70 patients two years post-treatment who had 
been randomly assigned to receive high-dose chemotherapy (N=34) or standard-dose 
chemotherapy (N=36) and a control group of breast cancer patients matched on age and 
time since treatment who had not received chemotherapy (N=34).  Patients were assessed 
with neuropsychological measures of verbal function, memory, attention/concentration, 
speed of information processing, motor function, visuoconstructional function, and 
mental flexibility.  An overall score of cognitive impairment (OSCI) was calculated for 
each patient by counting all tests on which the patient was impaired.  Impairment was 
defined for the chemotherapy groups as scoring two standard deviations below the mean 
score of the control group on that test.  Impairment for the control group was defined as 
scoring in the fifth percentile of the control patients for that test.  On the checklist, the 
high-dose and standard-dose chemotherapy groups did not significantly differ from each 
other.  Both chemotherapy groups scored significantly higher than the control group for 
complaints on the checklist items related to concentration, memory, and language.  For 
the EORTC-CF there was no significant difference between the two chemotherapy 
groups, and only the high-dose chemotherapy group scored significantly higher than the 
control group.  The checklist and the EORTC-CF were significantly correlated with each 
other.  The EORTC-CF and the checklist concentration, memory, and thinking questions 
were also significantly correlated with measures of anxiety and depression.  No 
relationship existed between either measure of cognitive complaints and the OSCI (range 
r = -.03 to .08). 
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Schagen et al. (1999) used the same measures of cognitive complaints as van Dam 
et al. (1998) to assess breast cancer patients two years post-treatment.  The sample in this 
study consisted of patients who were treated with conventional chemotherapy (N=39) and 
the control group from the van Dam et al. (1998) study (N=34).  These patients received 
the same neuropsychological measures as in the previously discussed study and 
impairment was also defined in the same way.  On the checklist, the chemotherapy 
patients reported significantly more complaints in concentration and memory than the 
control group.  No significant group differences existed for the checklist items about 
thinking and language.  Chemotherapy patients scored significantly higher on the 
EORTC-CF than the healthy controls.  Scores on the checklist and on the EORTC-CF 
were not significantly related to the OSCI or to any of the domain scores of the 
neuropsychological tests (range r = -.20 to .08).  The checklist and the EORTC-CF were 
significantly correlated with each other and with measures of anxiety and depression.   
Schagen et al. (2002) reassessed the samples from the van Dam et al. (1998) study 
and the Schagen et al. (1999) study two years after the initial testing using the same 
cognitive complaints measures and neuropsychological measures.  The sample consisted 
of three groups: high-dose and standard-dose chemotherapy patients (N=45) from the van 
Dam et al. study (1998); conventional chemotherapy patients (N=31) from the Schagen et 
al. study (1999), and the control group used in both previously mentioned studies (N=27).  
At four years post-treatment there were no significant differences in scores on the 
checklist and scores on the EORTC-CF among the high-dose group, the standard-dose 
group, and the control group.  Patients in the conventional chemotherapy group reported 
significantly more cognitive complaints than the control group on the checklist questions 
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of concentration and memory and on the EORTC-CF.  The correlations between 
cognitive performance and cognitive complaints for all groups were low and 
nonsignificant (range r =.19-.22).  The relationship between the changes in cognitive 
performance and the changes in cognitive complaints assessed by the checklist was 
characterized as negligible.   
Harder et al. (2002) used the EORTC-CF and a rating by a neuropsychologist to 
measure cognitive complaints in 40 patients who had completed allogeneic BMT 22 to 82 
months earlier.  Based on an interview, the neuropsychologist rated the extent of the 
patient’s cognitive problems on a four-point Likert-type scale (0=no problem, 1=mild 
problems, 2=moderate problems, 3=severe problems).  Patients were assessed on 
neuropsychological measures of general intelligence and conceptual reasoning, verbal 
function, memory, attention functions and concentration, executive functions, visual 
spatial and visuoconstructive ability, psychomotor function, and speed of information 
processing.  The EORTC-CF was significantly positively correlated with fatigue.  Total 
neuropsychological impairment, defined as the number of tests the patient scored two 
standard deviations below healthy population norms, was significantly negatively 
correlated with the EORTC-CF (r = -.55).  There was no relationship between total 
neuropsychological impairment and the neuropsychologist’s rating (values not reported). 
In summary, studies evaluating group differences yield mixed support for the 
validity of each cognitive complaint measure.  For the one study that used the MOS 
Cognitive Functioning Scale (Klein et al., 2002), glioma patients treated with or without 
radiotherapy reported significantly greater cognitive complaints in comparison to 
published data on healthy controls.  The finding that glioma patients reported greater 
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cognitive complaints is consistent with expectations, providing support for the validity of 
the MOS Cognitive Functioning Scale.  However, the MOS Cognitive Functioning Scale 
did not detect group differences between the glioma patients treated with radiotherapy, 
the glioma patients treated without radiotherapy, and the patients with hematological 
cancer.  As group differences would be expected, these findings do not support the 
validity of the MOS Cognitive Functioning Scale. 
In the one study that used the Squire Memory Self-Rating Questionnaire (Ahles et 
al., 2002), one of the three factors of the questionnaire (working memory) was 
significantly lower for breast cancer patients treated with chemotherapy than breast 
cancer patients treated with local therapy.  This finding would be expected and, therefore, 
supports the validity of the working memory factor of the Squire Memory Self-Rating 
Questionnaire.  However, no group differences were found for the other two factors of 
new learning and remote retrieval.  Taken together, these findings provide very limited 
support for the validity of this measure.  
Severely fatigued breast cancer patients were found to score significantly higher 
on the CIS, SIP Alertness Intellectual scales, and ratings of daily complaints of memory 
or concentration than nonseverely fatigued breast cancer patients and healthy controls 
(Servaes et al., 2002).  These results are consistent with the expectation that severely 
fatigued patients would have the most cognitive complaints, and provides support for the 
validity of the CIS, SIP Alertness Intellectual scales, and ratings of daily complaints of 
memory or concentration.  Findings also indicated that scores on the CIS, SIP Alertness 
Intellectual scales, and ratings of daily complaints of memory or concentration did not 
differ between nonseverely fatigued breast cancer patients and healthy controls (Servaes 
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et al., 2002).  However, it would be expected that cancer patients would have greater 
cognitive complaints and the lack of group differences does not provide support for the 
three measures.  The CIS, SIP Alertness Intellectual scales, and ratings of daily 
complaints of memory or concentration did not detect significant differences between 
patients treated with radiotherapy and chemotherapy, no chemotherapy or radiotherapy, 
chemotherapy only, or radiotherapy only (Servaes et al., 2002).  This pattern of results 
does not support the validity of the CIS, SIP Alertness Intellectual scales, or ratings of 
daily complaints of memory or concentration, as group differences would be expected 
due to the different treatments.   
The checklist of cognitive complaints used in three of the studies (Schagen et al., 
1999, 2002; van Dam et al., 1998) yielded mixed results in detecting group differences.  
In one study, high-dose and standard-dose chemotherapy patients reported more 
complaints than healthy controls for the three questions assessing concentration, memory 
and language, but not the fourth question assessing thinking (van Dam et al., 1998).  
Since it would be expected that cancer patients would have more cognitive complaints 
than healthy controls, results provide support for the validity of three out of the four 
questions.  Breast cancer patients treated with conventional chemotherapy also reported 
more complaints about concentration and memory than healthy controls (Schagen et al., 
1999), supporting the validity of two out of the four questions.  This same sample of 
breast cancer patients treated with conventional chemotherapy reported greater 
complaints in concentration and memory than the healthy controls two years later 
(Schagen et al., 2002), again providing support for the validity of the questions assessing 
concentration and memory.  However, findings indicated that the question assessing 
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thinking did not yield group differences in all three studies.  This is contrary to what 
would be expected and, therefore, does not support the validity of that question.  Findings 
indicating that the checklist scores did not differ between the high-dose and the standard-
dose chemotherapy patients (van Dam et al., 1998) suggest that the checklist was unable 
to detect group differences based on treatment type.  A two year follow-up assessment 
conducted with this sample (Schagen et al., 2002) found no difference in cognitive 
complaints assessed by the checklist among high-dose patients, standard-dose patients, 
and healthy controls.  Group differences would be expected, and the lack of findings does 
not support the validity of the checklist.   
Mixed support was also found for the validity of the EORTC-CF based on the 
detection of group differences.  Findings indicating that scores on the EORTC-CF were 
higher for patients treated with high-dose chemotherapy than healthy controls (van Dam 
et al., 1998) support the validity of the EORTC-CF.  The EORTC-CF also detected group 
differences between breast cancer patients treated with conventional chemotherapy and 
healthy controls at an initial assessment (Schagen et al., 1999) and, again, two years later 
(Schagen et al., 2002).  The ability of the EORTC-CF to detect expected group 
differences between cancer patients and healthy controls supports the validity of the 
measure.  However, the EORTC-CF did not detect a difference between patients treated 
with high-dose chemotherapy and patients treated with low-dose chemotherapy (van Dam 
et al., 1998).  It would be expected that patients treated with high-dose chemotherapy 
would have more cognitive complaints than patients treated with low-dose chemotherapy.  
Assessments conducted two years later with the same samples of high-dose 
chemotherapy patients, low-dose chemotherapy patients, and healthy controls found no 
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group differences in EORTC-CF scores (Schagen et al., 2002).  The lack of group 
differences at this assessment does not support the validity of the EORTC-CF. 
Mixed support was also obtained for other aspects of validity.  Five of the eight 
studies used multiple measures to assess cognitive complaints.  Evidence of concurrent 
validity was found in three studies (Schagen et al., 1999, 2002; van Dam et al., 1998) in 
which the EORTC-CF was shown to be significantly correlated with a checklist of 
cognitive complaints.   
Three studies demonstrated convergent validity for the EORTC-CF with anxiety 
and depression (Cull et al., 1996; Schagen et al., 1999; van Dam et al., 1998) and three 
studies demonstrated convergent validity for the EORTC-CF with fatigue (Cull et al., 
1996; Harder et al., 2002; Servaes et al., 2002).  Convergent validity for the EORTC-CF 
with health related quality of life was not supported in one study (Cull et al., 1996) 
All eight of these studies compared cognitive complaints to cognitive 
performance.  Six studies (Ahles et al., 2002; Cull et al., 1996; Schagen et al., 1999, 
2002; Servaes et al., 2002; van Dam et al., 1998) found no significant relation between 
cognitive complaints and cognitive performance.  One study (Klein et al., 2002) found 
scores for the MOS Cognitive Functioning Scale to be moderately correlated with 
neuropsychological measures assessing memory, attention, psychomotor speed, and 
graphomotor speed.  Another study (Harder et al., 2002) reported a significant correlation 
between the EORTC-CF and a composite score for neuropsychological measures.   
Taken together, these results yield mixed support for the validity of measures 
currently used to assess cognitive complaints in cancer patients.  The general lack of 
correspondence between measures of cognitive complaints and measures of cognitive 
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performance is particularly notable.  One reason may be that cognitive complaints and 
neuropsychological functioning have been examined as continuous variables.  Their 
relationship may only be apparent if contrasting groups are used and the relationship of 
cognitive complaints to impaired versus non-impaired subjects on neuropsychological 
functioning is examined. 
The Functional Assessment of Cancer Therapy Cognitive Scale 
 The FACT-Cog is a measure of cognitive complaints that was recently developed 
by Wagner and colleagues (2002).  This instrument was created by first obtaining 
qualitative data from oncology providers and patients on the perceived impact of 
chemotherapy on cognitive functioning and associated impairments in quality of life.  
Next, individual interviews were conducted with oncologists, oncology nurses, and 
cancer patients.  Cancer patients also participated in focus groups.  The most commonly 
described deficits were memory loss and forgetfulness, impaired concentration, word-
finding difficulties, fatigue, and frustration with these deficits.  The oncologists and 
nurses reported that these deficits impair patients’ ability to comprehend medical 
instructions and adhere to medication regimens.  The patients reported that these deficits 
interfere in social and work functioning (Wagner et al., 2002). 
Based on these findings, 51 items were created to assess a cognitive domain, an 
impact on functioning domain, and an impact on quality of life domain.  The cognitive 
domain consists of subscales assessing mental acuity, concentration, verbal and 
nonverbal memory, and verbal fluency.  The impact on functioning domain consists of 
subscales assessing functional interference due to deficits, others observation of these 
deficits, and change from previous functioning.  The items in the cognitive domains and 
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impact on functioning domains are rated on a 5-point scale (0=Never, 1=About once a 
week, 2=Two to three times a week, 3=Nearly every day, 4=Several times a day) of how 
often each statement had occurred during the past seven days.  The eight items assessing 
impact on quality of life are administered twice.  The first time the respondents are asked 
to rate the items on the 5-point frequency scale described above and the second time the 
respondents are asked to rate the items on a 5-point severity scale (0=Not at all, 1=A little 
bit, 2=Somewhat, 3=Quite a bit, 4=Very much).  To minimize the impact of distress 
unrelated to cognitive abilities on responses, the FACT-Cog is primarily composed of 
behaviorally based items.  The scale was evaluated to be between a fifth and sixth grade 
reading level. 
Aims 
The previously discussed literature demonstrates the lack of reliable and valid 
measures currently available to assess cognitive complaints.  The most commonly used 
measure of cognitive complaints, the EORTC-CF, is of unknown reliability and has 
yielded mixed evidence of validity.  This state of affairs supports the development of a 
new measure, such as the FACT-Cog.  The literature has also demonstrated that a 
significant portion of BMT patients report cognitive complaints following treatment 
(Andrykowski et al., 1989, 1990; Harder et al., 2002; Hjermstad et al., 1999; Schagen et 
al., 2002; van Dam et al., 1998).  Patients undergoing a BMT receive high-dose 
chemotherapy, radiotherapy, or both to deliberately compromise the patient’s immune 
system.  The immune system is subsequently restored though induction of blood or 
marrow products obtained from the same person (autologous transplantation) or from a 
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donor (allogeneic transplantation).  These characteristics suggest that BMT patients are 
an important and appropriate sample for the current study. 
 The goal of the current study was to examine the psychometric properties of the 
FACT-Cog, a newly developed instrument designed to measure perceived cognitive 
deficits in people with cancer.  The first step was to determine internal consistency.  To 
evaluate concurrent validity, scores on the FACT-Cog were compared to scores on an 
established subjective measure of cognitive deficits, the EORTC-CF.  To evaluate 
convergent validity, scores on the FACT-Cog were compared to scores on established 
self-report measures of depression (Center for Epidemiological Studies Depression Scale 
[CES-D]; Radloff, 1977), anxiety (State Version of the State Trait Anxiety Inventory 
[STAI-S]; Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983), and fatigue (Fatigue 
Symptom Inventory [FSI]; Hann et al., 1998).  Also to evaluate convergent validity, 
scores on the FACT-Cog were compared to scores on an established measure of health-
related quality of life (Medical Outcome Study Short From [SF-36]; Ware, Snow, 
Kosinski, & Gandek, 1993).  To evaluate divergent validity, scores on the FACT-Cog 
were compared to scores on an established self-report measure of 
extroversion/introversion (NEO Five Factor Inventory Extroversion subscale [NEO-FFI]; 
Costa & McCrae, 1992a).  Finally, to evaluate criterion validity, scores on the FACT-Cog 
were compared to scores derived from standardized neuropsychological measures. 
Hypotheses 
1. There will be a positive relationship between perceived cognitive deficits as 
measured by the FACT-Cog and scores on another established subjective measure 
of cognitive complaints. 
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 It is predicted that the total score on the FACT-Cog will be positively 
correlated with the total score on the EORTC-CF. 
2. There will be a positive relationship between perceived cognitive deficits as 
measured by the FACT-Cog and depression. 
 It is predicted that the total score on the FACT-Cog will be positively 
correlated with the total score on the CES-D. 
3. There will be a positive relationship between perceived cognitive deficits as 
measured by the FACT-Cog and anxiety. 
 It is predicted that the total score on the FACT-Cog will be positively 
correlated with the total score on the STAI-S. 
4. There will be a positive relationship between perceived cognitive deficits as 
measured by the FACT-Cog and fatigue. 
 It is predicted that the total score on the FACT-Cog will be positively 
correlated with the total score on the FSI Fatigue Disruptiveness Scale. 
5. There will be a positive relationship between perceived cognitive deficits as 
measured by the FACT-Cog and health-related quality of life. 
 It is predicted that the total score on the FACT-Cog will be negatively 
correlated with the physical component and mental component summary 
scales of the SF-36. 
6. There will be no relationship between perceived cognitive deficits as measured by 
the FACT-Cog and extroversion-introversion. 
 It is predicted that the total score on the FACT-Cog will not be correlated with 
the total score on the NEO-FFI Extroversion scale. 
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7a. There will be a negative relationship between perceived cognitive deficits as 
measured by the FACT-Cog and standardized neuropsychological measures. 
 It is predicted that the total score on the FACT-Cog will be negatively 
correlated with the total neuropsychological performance score.  If this 
prediction is supported, exploratory analyses will be conducted to examine 
relationships between individual subscales of the FACT-Cog and individual 
cognitive domains from the neuropsychological measures. 
7b. Cognitive deficits, as measured by the FACT-Cog, will be greater in patients 
classified as impaired on neuropsychological performance than in patients 
classified as non-impaired on neuropsychological performance. 
 It is predicted that the total score on the FACT-Cog will be significantly 
higher for impaired patients than non-impaired patients.  If this prediction is 
supported, exploratory analyses will be conducted to examine group 
differences for individual subscales of the FACT-Cog. 
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Method 
Participants 
 Participants were men and women currently enrolled in a study titled “Cognitive 
Function in Patients Undergoing Blood and Marrow Transplantation” at Moffitt Cancer 
Center.  Eligibility criteria for the aforementioned study were: 1) age between 18 and 75 
years; 2) completion of at least 8 years of formal education; 3) the ability to speak and 
read standard English; and 4) acceptance into the Moffitt BMT program.  Additional 
criteria for the current study were that participants in the aforementioned study were 
returning to Moffitt to receive neuropsychological testing at either a 6-month or 12-
month follow-up assessment. 
Procedure 
 Patients who are identified as BMT candidates are routinely scheduled for a 
psychosocial evaluation comprised of a clinical interview with a social worker and a brief 
evaluation with a psychologist to identify psychological problems and assess quality of 
life.  From this standard pre-BMT psychosocial evaluation, patients were recruited for the 
aforementioned BMT study and randomly assigned to one of three neuropsychological 
testing groups.  All participants completed psychosocial measures pre-BMT, 6-months 
post-BMT, and 12-months post-BMT.  Sixty percent of the participants (Group 1) were 
assessed with the neuropsychological battery pre-BMT, 6-months post-BMT, and 12-
months post-BMT.  Of the remaining 40 percent of participants, 20 percent received the 
neuropsychological battery 6-months post-BMT and 12-months post-BMT (Group 2), 
and 20 percent received the neuropsychological battery only at 12-months post-BMT 
(Group 3).  For the current study, data on estimated intellectual ability and extroversion 
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measured for all participants at the pre-BMT assessment were used.  The remaining 
psychosocial measures and neuropsychological tests were assessed once, at either 6-
months post-BMT or 12-months post-BMT according to the testing schedule listed 
above.  A trained research assistant administered the neuropsychological battery.  The 
psychosocial questionnaires were given to the participant to complete while at Moffitt or 
to be taken home and mailed back at the participant’s convenience using a postage paid 
envelope that was provided.  For their participation in the aforementioned BMT study, 
participants were paid 25 dollars upon completion of each of the post-BMT assessments, 
regardless of the group to which they were assigned.  
Measures 
Demographic, Disease, and Treatment Measures 
Demographic information was obtained through a background interview.  
Variables assessed include: date of birth, handedness, race, marital status, income, and 
education.  Electronic medical charts were reviewed to obtain information on cancer type, 
type of transplant, date of diagnosis, date of admittance, date of transplant, and date of 
discharge.   
Psychosocial Measures 
Perceived Cognitive Functioning.  Two instruments were used to assess perceived 
cognitive functioning: the Functional Assessment of Cancer Therapy Cognitive Scale and 
the EORTC QLQ-C30 Cognitive Functioning Scale.  The Functional Assessment of 
Cancer Therapy Cognitive Scale (FACT-Cog; Wagner et al., 2002) is a 51-item measure 
designed to assess subjective perception of cognitive deficits in cancer patients.  Items 
were written based on the most commonly identified themes obtained from focus groups 
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or individual interviews with oncologists, oncology nurses, and oncology patients.  Item 
formatting is based on the Functional Assessment of Chronic Illness Therapy (FACIT) 
measurement system.  The FACT-Cog yields four summary scores: 1) a cognitive 
domain score, consisting of mental acuity, concentration, verbal and nonverbal memory, 
and verbal fluency subscale scores; 2) an impact on functioning domain score, consisting 
of functional interferences, other people noticed deficits, and change from previous 
functioning subscale scores; 3) an impact on quality of life domain score; and 4) a total 
score.  Participants respond on a five-point Likert scale (0=Never to 4=Several times a 
day) how often each statement had occurred in the past seven days.  The eight items 
assessing impact on quality of life are administered a second time where patients respond 
on a five-point Likert scale (0=Not at all to 4=Very much) the frequency to which they 
have experienced each item.  The psychometric properties of this scale are currently 
being established.  The EORTC QLQ-C30 Cognitive Functioning Scale (EORTC-CF; 
Aaronson et al., 1993), consists of two items that measure subjective cognitive 
functioning.  Participants respond on a four-point Likert scale the extent to which they 
have experienced each cognitive complaint in the past week (1=Not at all to  4=Very 
much).  The EORTC QLQ-C30 Cognitive Functioning Scale has demonstrated validity 
with a sample of bone marrow transplant patients, with scores being correlated with total 
neuropsychological impairment (r = -.55, p<.001; Harder et al., 2002). 
Depression.  The Center for Epidemiological Studies – Depression (CES-D; 
Radloff, 1977) is a 20-item measure of depressive symptomotology.  The items were 
selected from a pool of items taken from previously validated depression scales, from the 
literature, and from factor analytic studies.  Respondents indicate on a four-point rating 
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scale (0= rarely or none of the time, 3= most or all of the time) the extent to which they 
experienced each depressive symptom during the past week.  The CES-D has good 
internal consistency with alphas of .85 for the general population and .90 for a psychiatric 
population (Radloff, 1977).  The validity of the CES-D has been demonstrated with a 
wide range of populations, including cancer patients (Beeber, Shea, & McCorkle, 1998; 
Hann, Winter, & Jacobsen, 1999). 
Anxiety.  The State form of the State-Trait Anxiety Inventory (STAI-S; 
Spielberger et al., 1983) is a 20-item inventory that measures the level of current anxiety.  
Participants respond on a four-point Likert scale (1=Not at all to 4=Very much so) the 
extent to which they endorse each item.  The internal consistency of the instrument 
ranges from .86 to .95 across male and female samples (Spielberger et al., 1983).  The 
STAI-S has validity correlations of .80 with other established anxiety measures 
(Spielberger et al., 1983).  
Fatigue.  The Fatigue Symptom Inventory (FSI; Hann et al., 1998) is a 14-item 
inventory designed to assess the frequency and severity of fatigue as well as its perceived 
disruptiveness.  Frequency is measured as the number of days in the past week (0-7) 
respondents felt fatigued as well as on average, the extent they felt fatigued each day 
(0=None to 10=Entire day).  Severity is measured on a separate 11-point scale (0=Not at 
all fatigued to 10=As fatigued as I could be) that assess most, least, and average fatigue 
during the past week as well as current fatigue.  Perceived disruptiveness is measured on 
a separate 11-point scale (0=No interference to 10=Extreme interference) that assess the 
degree to which fatigue in the past week was judged to interfere with general level of 
activity, ability to bathe and dress, normal work activity, ability to concentrate, relations 
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with others, enjoyment of life, and mood.  The interference ratings can also be summed to 
obtain a total disruptiveness score.  Previous research has demonstrated the reliability and 
validity of the FSI with individuals diagnosed with cancer (Hann et al., 1998). 
Health-Related Quality of Life.  The Medical Outcome SF-36 Health Survey (SF-
36; Ware et al., 1993) is a 36-item measure of various aspects of perceived health, 
functioning, and quality of life.  It contains eight subscales that measure the extent to 
which health status impacts each of the following areas; 1) physical functioning; 2) role 
functioning-physical; 3) bodily pain; 4) general health; 5) vitality; 6) social functioning; 
7) role functioning- emotional; and 8) mental health.  The SF-36 also yields two 
summary scores that measure global physical functioning (physical component summary 
scale) and global mental health functioning (mental component summary scale).  The 
items use Likert-type scales, some with five or six points and others with two or three 
points.  Correlations ranging from .52 to .78 have been reported between the SF-36 
subscales and other QOL measures (Ware & Sherbourne, 1992; McHorney, Ware, & 
Raczek, 1993).  Test-retest reliability coefficients range from .68-.93 for the various 
subscales.  The SF-36 has been found to have acceptable reliability and validity when 
administered to healthy and chronically ill individuals (Ware et al., 1993). 
Extroversion and Neuroticism.  The Neuroticism, Extroversion, and Openness – 
Five-Factor Inventory (NEO-FFI; Costa & McCrae, 1992a) is a 60-item personality 
measure based on the five-factor model of personality.  The five factors assessed are 
Neuroticism, Extroversion, Openness, Agreeableness, and Conscientiousness.  Responses 
are made on a five-point scale ranging from strongly disagree to strongly agree.  Factor 
analyses have provided support for these factors with coefficient alphas for the five 
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domain scores ranging from .86 to .95 and test-retest coefficients ranging from .63 to .81 
(Costa & McCrae, 1992b, c).  For the purpose of this study, only the Extroversion and 
Neuroticism scales were examined. 
Neuropsychological Measures 
Estimated Intellectual Functioning.  The National Adult Reading Test (NART; 
Nelson, 1982) contains 50 irregular words that cannot be easily phonetically decoded.  
Inter-rater reliability is high ranging from .96 to .98 and test-retest reliability is high at 
.98 (Crawford, Parker, Stewart, Besson, & De Lacey, 1989).  Previous studies have 
shown that performance on the NART is highly correlated with the general factor of 
intelligence ‘g’ from the Wechsler scales (Crawford et al., 1989). 
Attention.  The Conners’ Continuous Performance Test (CPT-II; Conners, 2000) 
is a measure of sustained attention administered on the computer.  Participants monitor a 
random series of single numbers or letters, which are presented continuously.  They are 
asked to indicate that they have detected a target event by pressing the space bar while 
avoiding responding to distracting stimuli.  The CPT-II yields three scores: impulsivity, 
vigilance, and inattention. Test-retest reliability is high at .92 and validity of the CPT-II 
has been demonstrated with neurological, clinical, and nonclinical populations (Conners, 
2000). 
Memory.  Memory was assessed using three measures: the California Verbal 
Learning Test; the Logical Memory subtest from the Wechsler Memory Scale-III (WMS-
III); and the Visual Reproduction subtest from the WMS-III.  The California Verbal 
Learning Test (CVLT; Delis, Kramer, Kaplan, & Ober, 1987) assesses verbal learning 
and memory.  The test consists of five presentations and recall of a 16-item list of words 
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belonging to four semantic categories.  An interference list of 16-items containing eight 
words from two shared semantic categories is presented, followed by free recall and a 
category-cued recall of the original list.  Retention is tested 20 minutes after learning by 
free recall, category-cued recall, and recognition.  Split-half reliability and coefficients 
alpha are in the moderate to high range (Delis et al., 1987).  The CVLT correlates well 
with other measures of memory and learning (Spreen & Strauss, 1998).  The Logical 
Memory subtest from the WMS-III (Wechsler, 1997) assesses memory for prose.  Two 
short stories are read aloud to the participant followed by immediate and delayed recalls 
and a recognition paradigm.  Internal consistency assessed by split-half reliability ranges 
between .67 and .80 and the inter-scorer reliability coefficient is .99 (Wechsler, 1997).  
The Visual Reproduction subtest from the WMS-III (Wechsler, 1997) assesses nonverbal 
memory for designs.  Five novel designs are each presented individually for 10 seconds, 
and the participant is asked to reproduce the design from memory.  After a 30 minutes, 
delayed recall and recognition paradigm are performed.  Reliability coefficients for 
immediate recall and delayed recall are .59 and .46.  Inter-scorer reliability is reported at 
.97 (Wechsler, 1997). 
Executive Functioning.  Executive functioning was assessed using four 
instruments: 1) Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol, 2) 
Trail Making Test, 3) Controlled Oral Word Association, and 4) Stroop 
Neuropsychological Screening Test.  The WAIS-R Digit Symbol (Wechsler, 1981) is a 
test of sustained attention, psychomotor speed, and motor persistence.  It requires 
participants to match numbers with a geometric mark according to a designated code.  It 
is consistently noted to be the most sensitive Wechsler subtest to brain dysfunction 
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(Lezak, 1995).  Test-retest reliability ranges from .82-.86 for adults (Wechsler, 1997).  It 
has been shown to be a sensitive indicator of cognitive changes in BMT candidates 
(Ahles, Tope, Furstenberg, Hann, & Mills, 1996).  The Trail Making Test (TMT; Reitan 
& Wolfson, 1993) assesses the participant’s ability to follow a simple number sequence 
(Trails A) and their ability to follow a complex sequence of alternating numbers and 
letters (Trails B).  Extensive reliability data are presented in Spreen and Strauss (1998), 
including reliability coefficients of  .69 to .94 for Trail A, and .66 to .86 for Trail B.  
Strong validity of the TMT as an indicator of mild to severe cognitive dysfunction has 
been reported with Trails B more sensitive to deficits (Reitan, 1958).  The TMT has been 
shown to be sensitive to BMT treatment effects (Andrykowski et al., 1992).  The 
Controlled Oral Word Association (COWA) from the Multilingual Aphasia Examination 
(Benton & Hamsher, 1989) assesses the speed and ease of word production and is a 
measure of executive function (e.g., initiation, perseveration and effortful output).  
Participants are asked to generate as many words as possible beginning with a target 
letter provided by the examiner over a one-minute trial.  There are three trials and 
respondents are requested to not use proper nouns or the same words with different 
suffixes.  Inter-scorer reliability is excellent, and test-retest reliability ranges from .70 to 
.88, as reported in Spreen & Strauss (1998) who also report strong concurrent validity.  
The COWA has been shown to be a sensitive measure with BMT candidates (Ahles et al., 
1996).  The Stroop Neuropsychological Screening Test (Stroop; Trenarry, Crosson, 
DeBoe, & Leber, 1989) is a task of effortful attention and speed and is sensitive to subtle 
attentional deficits (Lezak, 1995; Spreen & Strauss, 1998).  The Stroop consists of two 
trials: one in which the subject reads the words printed on a page and one in which the 
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subject names the color of the ink that the word is printed in.  Test-retest reliability is 
high (.90) and validity data indicate that the Stroop can discriminate cognitively impaired 
groups from normal groups (Trenarry et al., 1989). 
Motor.  The Grooved Pegboard (Matthews & Klove, 1964) evaluates speeded 
manual dexterity.  It requires the participants to place ridged pegs in a 5 X 5 square array 
with slots that are at various orientations requiring rotation of the pegs for correct 
placement.  This level of complexity makes this task sensitive to general psychomotor 
slowing caused by medication and disease effects (Lezak, 1995).  Fatigue and treatment 
with BMT have been shown to negatively impact the time to complete this task 
(Andrykowski, 1992). 
Data Reduction 
In order to avoid Type I statistical errors, the 22 test scores generated from these 
measures were grouped into the following four cognitive domains as suggested by Lezak 
(1995): Attention (CPT); Memory (CVLT, Logical Memory, Visual Reproduction); 
Executive Functioning (Digit Symbol, TMT, COWA, Stroop); and Motor (Grooved 
Pegboard).  To accomplish this, raw scores were converted into z-scores according to 
published normative data (Heaton, 1992; Heaton, Grant, & Matthews, 1991; Spreen and 
Strauss, 1998; Wechsler, 1997) and then averaged according to domain.  A total 
neuropsychological performance index was computed for each subject by deriving the 
average z-score from the 22 measures. 
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Statistical Analyses 
 Descriptive statistics (mean and standard deviations) were used to characterize the 
demographic, disease, and treatment characteristics of the sample.  Cronbach alpha 
coefficients were calculated to evaluate internal consistency of the total score and domain 
scores of the FACT-Cog.  Prior to conducting the main analyses, exploratory analyses 
were conducted to examine the relationship of demographic and clinical variables to the 
FACT-Cog total score and domain scores.  
To test the first hypothesis, a correlational analysis was performed to compare the 
total score of the FACT-Cog with the total score on the EORTC-CF.  A correlational 
analysis was also performed to compare the FACT-Cog domain scores with the total 
score on the EORTC-CF.  To test the second hypothesis, a correlational analysis was 
performed to compare the total score of the FACT-Cog with the total score on the CES-
D.  A correlational analysis was also performed to compare the FACT-Cog domain 
scores with the total score on the CES-D.  To test the third hypothesis, a correlational 
analysis was performed to compare the total score of the FACT-Cog with the total score 
on the STAI-S.  A correlational analysis was also performed to compare the FACT-Cog 
domain scores with the total score on the STAI-S.  To test the fourth hypothesis, a 
correlational analysis was performed to compare the total score of the FACT-Cog with 
the total score on the FSI Fatigue Disruptiveness Scale.  A correlational analysis was also 
performed to compare the FACT-Cog domain scores with the total score on the FSI 
Fatigue Disruptiveness Scale.  To test the fifth hypothesis, a correlational analysis was 
performed to compare the total score of the FACT-Cog with the physical component and 
mental component summary scales of the SF-36.  A correlational analysis was also 
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performed to compare the FACT-Cog domain scores with the physical and mental 
component summary scales of the SF-36.  Additional correlational analyses were 
performed to compare the FACT-Cog total score and domain scores with the total score 
on the NEO-FFI Neuroticism scale.  To test the sixth hypothesis, a correlational analysis 
was performed to compare the total score of the FACT-Cog with the total score on the 
NEO-FFI Extroversion scale.  A correlational analysis was also performed to compare 
the FACT-Cog domain scores with the total score on the NEO-FFI Extroversion scale.  
To test the first part of the seventh hypothesis, a correlational analysis was performed to 
compare the total score of the FACT-Cog with the total neuropsychological performance 
score.  A correlational analysis was also performed to compare the FACT-Cog domain 
scores with the total neuropsychological performance score.  Correlational analyses were 
performed to compare the FACT-Cog total score and domain scores to the 
neuropsychological domain scores and individual test scores.  To test the second part of 
the seventh hypothesis, a correlational analysis was performed to compare the total score 
of the FACT-Cog for the patients classified as impaired and non-impaired on total 
neuropsychological performance.  A correlational analysis was also performed to 
compare the FACT-Cog domain scores for patients classified as impaired and non-
impaired on total neuropsychological performance.  Classification as impaired on total 
neuropsychological performance was defined as obtaining a z-score at or below –1.5 on 
three or more neuropsychological tests, similar to the definition used by Schagen et al. 
(2002).  Correlational analyses were performed to compare the FACT-Cog total score 
and domain scores for patients classified as impaired on neuropsychological domain 
scores and individual test scores.  Performance on individual domains was classified as 
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impaired if the mean z-score for the domain was at or below –1.5 or at least 50 percent of 
the z-scores comprising that domain were at or below –1.5 (Lezak, 1995).  Performance 
on individual test scores were classified as impaired if the z-score was at or below –1.5. 
In addition, multivariate analyses were conducted.  A multiple regression analysis 
was conducted for the FACT-Cog total score.  Demographic variables that were 
significantly correlated with the FACT-Cog total score were entered into the equation 
first.  Psychosocial variables that were significantly correlated with the FACT-Cog total 
score were then entered into the equation using a forward selection technique with a p < 
.05 selection criterion.  Multiple regression analyses were also conducted for each FACT-
Cog domain score using the same procedure.  A uniqueness index was calculated for each 
variable in the regression analyses by subtracting the variance accounted for by all the 
variables without the target variable from the total variance accounted for by all of the 
variables.   
 In order to determine the necessary sample size for correctional analyses, a power 
analyses was conducted.  With 81 participants (p < .05, two-tailed), there was power of 
.80 to detect a correlational coefficient of .30 (medium effect size; Cohen, 1988).   
   
  36
 
 
Results 
 A total of eighty-two participants completed the six-month or twelve-month 
follow-up assessment.  Participants ranged in age from 23 to 72 years old (M = 52.91; SD 
= 12.03) with a similar number of males (N = 42) and females (N = 40).  Education 
ranged from 8 to 23 years (M = 13.76; SD = 2.30) and estimated IQ (NART scores) 
ranged from 80 to 124 (M = 98.5; SD = 15.3).  A majority of these individuals were 
Caucasian (85%), married (79%), had received autologous stem cell transplantation 
(85.4%), and had been diagnosed with multiple myeloma (72%).  Approximately 49% of 
participants reported an annual household income of at least $40,000, 28% were working 
full-time, and 21% reported not working due to disability.  See Table 1 for complete 
demographic information and Table 2 for complete clinical characteristics. 
Relationship of FACT-Cog to Demographic Characteristics 
Exploratory analyses were conducted to determine the relationship between 
demographic variables and the FACT-Cog total score (see Table 3).  Gender was 
significantly associated with the total score, indicating that women had greater cognitive 
complaints (p < .01).  Age, estimated IQ, years of education, race, marital status, 
diagnosis, type of transplant, and time since transplant (6 month or 12 month follow-up) 
were not significantly correlated with the total score (p values > .05).  Internal 
consistency of the FACT-Cog total score was high (α = .983), demonstrating the 
reliability of the measure.  Exploratory analyses were also conducted with each of the 
FACT-Cog domain scores.  Gender was significantly associated with the cognitive 
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domain, interference of functioning domain, and quality of life domain (p values < .05).  
Estimated IQ was significantly correlated with the quality of life domain (p < .05).  Age, 
years of education, race, marital status, diagnosis, type of transplant, and time since 
transplant were not significantly correlated with any of the domain scores (p values > 
.05).  Internal consistency was high for the cognitive domain (α = .962), the interference 
of functioning domain (α = .959), and the quality of life domain (α = .957).  The FACT-
Cog domain scores were highly correlated with each other.  The highest correlation was 
between the cognitive domain and the interference of functioning domain (r = .92, p < 
.0001), followed by the interference of functioning domain and quality of life domain (r = 
.84, p < .0001).  The lowest correlation was between the cognitive domain and the quality 
of life domain (r = .78, p < .0001). 
Relationship of FACT-Cog to Psychosocial Variables 
 As hypothesized, the FACT-Cog total score was significantly correlated with the 
EORTC-CF supporting the concurrent validity of the measure (r = .66, p <.0001).  The 
FACT-Cog cognitive, interference of functioning, and quality of life domain scores were 
also significantly correlated with the EORTC-CF.  (r = .65, .68, and .57 respectively, p 
values < .0001).   
To test the convergent validity of the FACT-Cog, hypothesized relationships 
between the total score and psychosocial variables were tested.  As expected (see Table 
4), the FACT-Cog total score was significantly correlated with measures of depression, 
fatigue, anxiety, mental well-being, and physical well-being (p values < .01).  All three 
domain scores were also significantly correlated with measures of depression, fatigue, 
anxiety, mental well-being and physical well-being (p values < .05).   
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To assess divergent validity, the correlations of the FACT-Cog with extroversion, 
as measured by the NEO Personality Inventory, were examined.  Consistent with 
expectations, the FACT-Cog total score was not significantly correlated with 
extroversion (p > .05).  The cognitive domain score and the quality of life domain score 
were also not significantly correlated with extroversion (p > .05), however, the 
interference of functioning domain score was significantly correlated with extroversion (p 
< .05).   
The relationship of neuroticism with the FACT-Cog was also examined.  The 
FACT-Cog total score, cognitive domain score and interference of functioning domain 
score were significantly correlated with neuroticism (p < .05).  The quality of life domain 
score was not significantly correlated with neuroticism (p >.05). 
 An exploratory regression analysis was conducted to determine the relative 
contribution of psychosocial variables to the total variance of the FACT-Cog total score 
(see Table 5).  To control for the contribution of gender, which was significantly related 
to the FACT-Cog total score (p < .05), it was entered first.  After controlling for gender, 
the psychosocial variables that were significantly correlated with the total score in 
univariate analyses were entered into the equation using the forward selection technique 
with a p < .05 selection criterion.  Gender accounted for 9% of the variance in the FACT-
Cog.  Fatigue entered the model on the second step and accounted for 23% of the 
remaining variance (p < .0001).  The final variable to enter the model was mental well-
being, which accounted for 5% of the remaining variance (p < .05).  Together, these 
variables accounted for 37% of the total variance in the FACT-Cog.  Physical well-being, 
anxiety, neuroticism and depression did not account for significant additional variance.   
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 Regression analyses were also conducted for each FACT-Cog domain score using 
the previously described method.  For the cognitive domain (see Table 6), gender was 
entered into the equation first and accounted for 9% of the variance.  Mental well-being 
entered into the equation next accounting for 18% of the remaining variance (p < .0001).  
Together, these variables accounted for 27% of the total variance in the FACT-Cog 
cognitive domain.  Fatigue, neuroticism, anxiety, depression, and physical well-being did 
not account for significant additional variance.  For the interference of functioning 
domain (see Table 7), gender was controlled for and accounted for 10% of the variance.  
Mental well-being entered into the equation next accounting for 22% of the remaining 
variance (p < .0001).  Together, these variables account for 32% of the total variance in 
the FACT-Cog interference of functioning domain.  Fatigue, extroversion, anxiety, 
depression, and physical well-being did not account for significant additional variance.  
For the quality of life domain (see Table 8), gender and IQ were entered into the equation 
first and accounted for 10% of the variance.  Fatigue entered into the equation next 
accounting for 26% of the remaining variance (p < .0001).  Together, these variables 
account for 36% of the total variance in the FACT-Cog quality of life domain.  Mental 
well-being, anxiety, depression, and physical well-being did not account for significant 
additional variance. 
 A uniqueness index was calculated to determine the variance accounted for that is 
unique to each variable.  For the total score (see Table 5), gender contributed the largest 
amount of unique variance (4%) followed by fatigue (3%) and mental well-being (2%).  
Neuroticism and anxiety each accounted for 1% of unique variance.  Depression and 
physical well-being each accounted for less than 1% of unique variance in the FACT-Cog 
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total score.  For the cognitive domain score (see Table 6), gender and neuroticism each 
contributed the largest amount of unique variance (4%) followed by anxiety (2%).  
Mental well-being, fatigue, and depression each accounted for 1% of unique variance, 
and physical well-being accounted for less than 1% of unique variance.  For the 
interference of functioning domain (see Table 7), gender contributed the largest amount 
of unique variance (5%) followed by mental well-being (4%).  Fatigue and extroversion 
each contributed 2% of unique variance and anxiety contributed 1% of unique variance.  
Physical well-being and depression each contributed less than 1% of unique variance.  
For the quality of life domain (see Table 8), fatigue contributed the most unique variance 
(3%).  Gender and mental well-being each contributed 1% of unique variance.  Estimated 
IQ, depression, physical well-being, and anxiety each accounted for less than 1% of 
unique variance. 
Relationship of FACT-Cog to Neuropsychological Variables 
 Contrary to expectations, the FACT-Cog total and domain scores were not 
significantly related to the total neuropsychological performance score (see Table 9).  
The lack of significant findings may be a result of a decrease in sensitivity due to the 
averaging of multiple tests assessing different aspects of cognitive functioning.  
Therefore, exploratory analyses were conducted to correlate the FACT-Cog with the 
neuropsychological domain scores and individual test scores (see Tables 9 and 10).  The 
FACT-Cog total and domain scores were not significantly correlated with the four 
domain scores (memory, executive functioning, motor, and attention).  With regards to 
individual test scores, a significant correlation was found between the quality of life 
domain score and the vigilance subscale of the CPT-II (p < .05), with higher cognitive 
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complaints being related to lower vigilance.  All other correlations between the FACT-
Cog total and domain scores and the individual neuropsychological test scores were non-
significant. 
To determine if patients with greater cognitive complaints had greater impaired 
performance on neuropsychological tests (see Table 11), neuropsychological test scores 
were dichotomized into impaired or non-impaired based on the previously described 
criterion.   The FACT-Cog total and domain scores were not significantly correlated with 
impairment classification based on the total neuropsychological performance score.  As 
previously mentioned, these results may be a related to of loss of sensitivity, therefore 
exploratory analyses were conducted.  The FACT-Cog total and domain scores were not 
significantly correlated with the four neuropsychological domain scores (see Table 11).  
When individual neuropsychological test scores were examined, significant correlations 
did arise with the CPT-II subscales with higher cognitive complaints associated with 
impaired performance (see Table 12).  Impaired performance on the CPT-II impulsivity 
subscale was significantly correlated with the FACT-Cog total score and the three 
domain scores (p < .05).  The FACT-Cog total score and quality of life domain score 
were also significantly correlated with the CPT-II vigilance subscale (p < .05).  The 
direction of these relationships is for impaired performance to be associated with more 
cognitive complaints.  In addition, the FACT-Cog cognitive domain score was 
significantly correlated with the short delay cued recall score and the long delay free 
recall score of the CVLT (p < .05).  The direction of this relationship is for impaired 
performance to be associated with fewer cognitive complaints.   
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To better understand the results, the rates of impairment were examined.  The 
Grooved Pegboard (dominant and nondominant hand) had the highest rates of 
impairment of individual tests (26.8% and 31.7% respectively).  The COWA had the next 
highest rate at 13.4%.  For all of the other individual tests, the percentage of scores 
classified as impaired ranged from 8.5% to 1.2%.  Rate of impairment in the domain 
scores were also low, except for the motor domain which had the highest impairment rate 
at 37.8%.  The memory domain and the executive functioning domain each had an 
impairment rate of 3.7%.  The attention domain had the lowest rate of impairment at 
2.4%.    
Relationship of EORTC-CF to Demographic Variables 
Parallel analyses were performed to study the relationship of the EORTC-CF and 
the demographic, psychosocial, and neuropsychological variables.  The EORTC-CF was 
significantly related to gender (p = .04), with women having greater cognitive 
complaints, type of transplant (p = .01), with patients who received an autologous 
transplantation having greater cognitive complaints than patients who received an 
allogeneic transplantation, and race (p = .05), with Caucasians having more cognitive 
complaints than non-Caucasians (see Table 3).  Age, estimated IQ, years of education, 
marital status, diagnosis, and time since transplant were not significantly correlated with 
the EORTC-CF (p values > .05).  The EORTC-CF had strong internal consistency (α = 
.77).   
Relationship of the EORTC-CF to Psychosocial Variables 
The EORTC-CF was significantly correlated with depression, fatigue, anxiety, 
mental well-being, and physical well-being (p values < .001; see Table 3).  The EORTC-
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CF was also significantly correlated with extroversion (p < .001), but not with 
neuroticism (p >.05; see Table 3).   
A regression analysis was conducted with the EORTC-CF to examine which 
psychosocial variables accounted for a significant amount of the variance (see Table 13).  
Type of transplant, gender, and race were significantly correlated with the EORTC-CF in 
univariate analyses, therefore, these three variables were controlled for by being entered 
into the equation first.  Next, the psychosocial factors were entered using a forward 
selection technique with a p < .05 selection criterion.  Type of transplant, gender, and 
race accounted for 16% of the variance in the EORTC-CF.  Mental well-being entered 
the model in the second step accounting for 20% of the remaining variance (p < .0001).  
Together, these variables account for 37% of the total variance in the EORTC-CF.  
Physical well-being, extroversion, fatigue, anxiety, and depression did not account for 
significant additional variance.   
A uniqueness index was calculated to determine the amount of unique variance 
each psychosocial variable contributed (see Table 13).  Type of transplant accounted for 
the most unique variance (6%), followed by extroversion (3%).  Gender, race, and mental 
well-being each accounted for 2% of unique variance in the EORTC-CF.  Fatigue 
accounted for 1% of unique variance and physical well-being, anxiety, and depression 
each accounted for less than 1% of unique variance. 
Relationship of the EORTC-CF to Neuropsychological Variables 
The EORTC-CF was not significantly correlated with the total 
neuropsychological performance score (see Table 9).  As previously stated, the lack of 
significant findings may be a result of a decrease in sensitivity due to the averaging of 
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multiple tests.  Exploratory analyses found that the EORTC-CF was not significantly 
correlated with the four neuropsychological domain scores (see Table 9).  With regards to 
individual test scores (see Table 10), the EORTC-CF was significantly correlated with 
the impulsivity subscale of the CPT-II (p < .05).  The direction of this relationship is for 
impaired performance to be associated with more cognitive complaints. 
The EORTC-CF was correlated with neuropsychological tests scores that were 
classified as impaired or non-impaired, based on previously described criterion, to 
determine if patients with greater complaints had greater impaired performance (see 
Table 11).  The correlations between the EORTC-CF and impairment classification of the 
total score were nonsignificant.  This finding may be a result of lack of sensitivity, 
therefore exploratory analyses were conducted.  No significant correlations were found 
between the EORTC-CF and impairment of any domain scores (see Table 11).  When 
looking at individual test scores (see Table 12), the EORTC-CF was significantly 
positively correlated with impairment classification for the delayed visual reproduction 
score (p < .05), the inattention subscale of the CPT-II (p < .05), and the impulsivity 
subscale of the CPT-II (p < .01).  The direction of these relationships is for impaired 
performance to be associated with more cognitive complaints. 
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Discussion 
The aim of the current study was to examine the psychometric properties of the 
FACT-Cog, a recently developed instrument designed to measure perceived cognitive 
deficits in people with cancer.  The following section will first evaluate the reliability and 
validity of the FACT-Cog.  Second, additional demographic and multivariate analyses 
conducted will be reviewed.  Next, the FACT-Cog will be compared with the EORTC-
CF, an established measure of cognitive complaints.  Finally, limitations of this study, 
clinical implications, and future directions for research will be discussed.   
Reliability 
The reliability of the FACT-Cog total score was strong, as evidenced by its high 
internal consistency.  The FACT-Cog cognitive, interference of functioning, and quality 
of life domain scores also demonstrated high internal consistency.  Test-retest reliability 
was not evaluated and thus remains unknown.   
Concurrent Validity 
 As hypothesized, the FACT-Cog total score was significantly correlated with the 
EORTC-CF.  This significant relationship with an established measure of cognitive 
complaints provides support for the concurrent validity of the FACT-Cog total score.  
The concurrent validity of the three FACT-Cog domain scores was also supported by 
their significant relationships with the EORTC-CF.   
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Convergent Validity 
As hypothesized, the FACT-Cog total score was significantly correlated with 
measures of depression, fatigue, anxiety, mental well-being, and physical well-being.  
These findings provide evidence for the convergent validity of the FACT-Cog.  The same 
pattern of results was found for the FACT-Cog domain scores.  Additional analyses were 
conducted to examine the relationship of neuroticism to the FACT-Cog total and domain 
scores.  Although no a priori hypothesis about this relationship was made, previous 
research has found that people with cancer who are high on neuroticism often report 
worse psychosocial outcomes (Aarstad, Aarstad, Birkhaug, Bru, & Olofsoon, 2003).  
Therefore, it would be expected that patients high on neuroticism would have greater 
cognitive complaints.  Results for the FACT-Cog total score and cognitive domain and 
interference of functioning domain scores supported this expectation.  The FACT-Cog 
quality of life domain score, however, was not significantly correlated with neuroticism. 
These results are consistent with previous research that has found cognitive 
complaints to be significantly related to psychosocial factors.  More specifically, the 
significant relationship between depression and cognitive complaints was found in 
research with cancer patients by Cull et al. (1996), Schagen et al. (1999), and van Dam et 
al. (1998) using other cognitive complaints measures.  The results of this study, regarding 
the relationship of fatigue and cognitive complaints, were also consistent with previous 
research with cancer patients (Cull et al., 1996; Harder et al., 2002; Servaes et al., 2002).  
The significant relationship between anxiety and cognitive complaints in this study is 
consistent with the previous cancer research as well (Cull et al., 1996; Schagen et al., 
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1999; Van Dam et al., 1998).  Previous research has not looked specifically at 
relationship with measures of mental well-being and physical well-being.    
Although the FACT-Cog was significantly correlated with measures of depression 
and fatigue, the FACT-Cog shared only 25% of its variance with depression and 28% of 
its variance with fatigue.  This suggests that cognitive complaints is a distinct construct 
from depression and fatigue. 
Divergent Validity 
As hypothesized, the FACT-Cog total score was not correlated with a measure of 
extroversion.  This finding reflects the expected pattern for divergent validity.  There was 
mixed support for the divergent validity of the FACT-Cog domain scores.  As expected, 
the cognitive and quality of life domains were not significantly correlated with 
extroversion, however, the interference of functioning domain was significantly 
correlated with extroversion.   
Previous research has not examined the divergent validity of cognitive complaints 
measures.  This is the first study to examine the relationship of cognitive complaints to 
extroversion to assess divergent validity.  Previous research has not found a significant 
relationship between extroversion and depression (Van der Zee, Buunk, Sanderman, 
Botke, & Van der Bergh, 1999), or between extroversion and quality of life (Aarstad et 
al., 2003) in cancer patients.    
Criterion Validity 
Hypotheses regarding the criterion validity of the FACT-Cog were generally not 
supported.  Contrary to predictions, the FACT-Cog total and domain scores were not 
significantly related to the total and domain scores for the neuropsychological measures.  
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Likewise, when the neuropsychological total and domain test scores were dichotomized 
as impaired or nonimpaired, no significant relationships were found with the FACT-Cog 
scores. 
 To rule out the possibility that the lack of significant findings may have been 
related to a loss of sensitivity due to the averaging of multiple tests assessing different 
aspects of cognitive performance, the relationship of the FACT-Cog total and domain 
scores to individual neuropsychological test scores was also examined.  These analyses 
did yield a limited number of significant findings.  The FACT-Cog quality of life domain 
was significantly correlated with continuous scores on the vigilance subscale of the CPT-
II.  When neuropsychological performance was classified as impaired or nonimpaired, 
the impulsivity subscale of the CPT-II was significantly correlated with the FACT-Cog 
total score and all three FACT-Cog domain scores.  The vigilance subscale was 
significantly correlated with the FACT-Cog total score and quality of life domain score.  
In all of these instances, poorer performance on the CPT-II was associated with greater 
cognitive complaints.  The short delay cued recall and the long delay free recall subscales 
of the CVLT test in the memory domain were also significantly related to the FACT-Cog 
cognitive domain score.  In this instance, better performance on the CVLT was associated 
with greater cognitive complaints.   
Of note, few participants had impaired performance on the neuropsychological 
tests.  However, the increased number of significant relationships when the scores are 
dichotomized suggests that there are subcategories of cognitive performance.  Although 
no other correlations between the FACT-Cog and neuropsychological test scores were 
significant, tests in the memory domain and motor domain had small to medium effect 
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sizes for correlational analyses (r = .15 to .19) as suggested by Cohen (Cohen, 1987).  
This suggests that there may be a power issue, in that the sample size was too small to 
detect significant findings of these more subtle effects. 
In general, the lack of significant correlations between cognitive complaints and 
cognitive performance found in this study is consistent with the literature on cancer 
patients.  Ahles et al. (2002) found that correlations between neuropsychological domain 
scores and cognitive complaints were nonsignificant.  Van Dam et al. (1998) and 
Schagen et al. (1999, 2002) also found no significant relationship between cognitive 
complaints and neuropsychological total and domain scores.  Two studies that examined 
the relationship between cognitive complaints and individual neuropsychological test 
scores have also reported nonsignificant relationships (Cull et al., 1996; Servaes et al., 
2002).  However, Klein et al. (2002) did find significant correlations between cognitive 
complaints and individual test scores measuring memory, attention, psychomotor speed, 
and graphomotor speed.  Only one study reported results generally inconsistent with the 
current study’s findings.  Harder et al. (2002) reported a significant correlation between 
cognitive complaints as measured by the EORTC-CF and a total neuropsychological 
impairment performance score.  With regards to criterion validity, the FACT-Cog cannot 
be considered superior to existing measures of cognitive complaints.   
Demographic and Multivariate Analyses 
When examining the relationship of the FACT-Cog total and domain scores to 
demographic variables, all FACT-Cog scores were significantly correlated with gender, 
with women having more cognitive complaints than men.  The FACT-Cog quality of life 
domain score was also significantly related to estimated IQ, with higher estimated IQ 
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associated with greater complaints.  The FACT-Cog total and domain scores were not 
significantly related to age, years of education, race, marital status, diagnosis, type of 
transplant, and time since transplant. 
The significant relationship between cognitive complaints and gender has not 
been found in previous research with cancer patients.  Few studies have reported testing 
for gender differences, but ones that did found no significant relationship between 
cognitive complaints and gender (Andrykowski et al., 1990; Cull et al., 1996; Hjermstad 
et al., 1999).  However, women have been found to report higher levels of neuroticism 
than men (Goodwin & Gotlib, 2004), and since neuroticism has been associated with 
more subjective health complaints in cancer patients (Aarastad et al., 2003), women may 
be expected to have more cognitive complaints than men.  One study found that cognitive 
complaints were related to years of education (Andrykowski et al., 1990), however, 
another study found no such relationship (Cull et al., 1996).  Consistent with this study, 
cognitive complaints were not significantly related to age in two studies (Andrykowski et 
al., 1990 & Cull et al., 1996).  Cull et al. (1996) also found that cognitive complaints 
were not significantly related to estimated IQ, which is consistent with the findings for 
the FACT-Cog total score and cognitive and interference of functioning domain scores.  
The current study found no significant difference between types of BMT.  This finding is 
inconsistent with one study that found patients who received autologous BMT had more 
complaints that patients who received allogeneic BMT (Hjermstad et al., 1999), but is 
consistent with other research that found so significant differences between different 
types of treatment groups (Cull et al., 1996; Schagen et al., 2002; Van Dam et al., 1998).   
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Regression analyses were conducted, controlling for significant demographic 
variables, to determine which psychosocial variables accounted for a significant amount 
of the variance in the FACT-Cog total score and domain scores.  Only fatigue and 
mental-well being accounted for a significant amount of the remaining variance in the 
FACT-Cog total score after controlling for gender.  For the FACT-Cog cognitive and the 
interference of functioning domain scores, only mental well-being accounted for a 
significant amount of the remaining variance after controlling for gender.  For the FACT-
Cog quality of life domain score, only fatigue accounted for a significant amount of the 
remaining variance after controlling for gender and estimated IQ.   
Fatigue and mental well-being were the only two psychosocial factors that 
contributed a significant amount of additional variance in the FACT-Cog total score and 
domain scores.  However, the small uniqueness index for all of the variables in the 
regression analyses indicates that there was significant overlap in the contributions of 
each variable.   
FACT-Cog Total Score in Comparison to the EORTC-CF 
 The FACT-Cog was designed to be a comprehensive measure of cognitive 
complaints.  Therefore, the psychometric properties of the FACT-Cog total score were 
compared to an established measure of cognitive complaints, the EORTC-CF.  Both 
measures demonstrated adequate internal consistency reliability, however, the FACT-Cog 
total score had a slightly higher internal consistency than the EORTC-CF (.98 vs. .77).  
The FACT-Cog total score and EORTC-CF provided equally strong evidence for 
convergent validity.  Both were significantly correlated with measures of depression, 
fatigue, anxiety, mental well-being and physical well-being.  While the FACT-Cog total 
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score demonstrated divergent validity with extroversion, the EORTC-CF was 
significantly correlated with extroversion.  Therefore the divergent validity of the 
EORTC-CF was not supported.  An additional analysis to examine the relationship 
between the EORTC-CF and neuroticism did not find a significant relationship as would 
be expected, and as found with the FACT-Cog total score.   
There was minimal support for criterion validity for both measures.  Neither the 
FACT-Cog total score nor the EORTC-CF was significantly correlated with total 
neuropsychological performance or with the neuropsychological domain scores 
(continuous or impairment classifications).  When the relationship to the individual test 
scores as continuous measures was examined, the EORTC-CF yielded similar results to 
the FACT-Cog total score, with a significant relationship with one of the CPT-II 
subscales.  Relationship of the EORTC-CF to individual test scores classified as impaired 
or nonimpaired also produced results similar to the FACT-Cog total score, with 
significant findings mainly within the attention domain.  Similar to the FACT-Cog total 
score, other correlations of individual tests with the EORTC-CF, although nonsignificant, 
had small to medium effect sizes.  Again, this suggests that power may have been an 
issue for both measures. 
When examining the relationship of the cognitive functioning measures to 
demographic and clinical variable, the FACT-Cog total score was significantly correlated 
with gender only, while the EORTC-CF was significantly correlated with gender, race, 
and type of BMT transplant.  There is no a priori reason to think that cognitive 
complaints should be related to race or type of BMT transplant.  In the absence of an a 
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priori reason, the relationship of the EORTC-CF to race and type of transplant is 
undesirable.   
Although these measures demonstrated similar psychometric properties, the 
content of the measures varies greatly.  A strength of the EORTC-CF is the brevity of the 
measure.  However, this brevity also means that the content of the EORTC-CF is very 
narrow assessing only memory and attention.  In comparison, a weakness of the FACT-
Cog is the length of the measure, but this allows the FACT-Cog to assess broader aspects 
of cognitive complaints.  Although in this sample the FACT-Cog domain scores had 
similar results to the FACT-Cog total score showing no clear advantage of domain 
scores, the utility of the FACT-Cog domain scores may yet be identified. 
Limitations 
Several limitations of the current study should be noted.  First, the cross-sectional 
design of the study did not allow test-retest reliability to be assessed to demonstrate the 
temporal stability of the measure.  Second, the cross-sectional design also meant that the 
neuropsychological measures and FACT-Cog were only administered once.  Therefore, 
how changes in cognitive performance may relate to changes in cognitive complaints 
could not be assessed.  Cognitive complaints may not reflect actual cognitive 
performance, rather they may reflect a change from previous functioning.  Looking at 
discrete cognitive performance in relationship to cognitive complaints may not be an 
accurate means of evaluating criterion validity.  Third, the sample size may have been too 
small to detect significant differences for small to medium effect sizes.  Fourth, the 
generalizabilty of these results may be limited to patients receiving a BMT.  Fifth, the 
sample was predominantly Caucasian, married, well-educated, and economically stable 
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potentially limiting the generalizabilty of the results to a more socioeconomically diverse 
group.  A final limitation is that the individual neuropsychological tasks generally did not 
require sustained effort.  Therefore these tasks may not have been demanding enough to 
simulate the types of cognitive complaints assessed by the FACT-Cog.  Anecdotally, 
patients reported that the CPT-II, a task lasting much longer than any other task, was 
demanding and required more sustained effort than the other tasks.  The significant 
relationships between the CPT-II subscales and the measures of cognitive complaints 
may reflect the need for additional tasks that require sustained effort.   
Clinical Implications 
 These results suggest, therefore, that caution should be used when interpreting 
patients’ cognitive complaints.  The overlap between cognitive complaints and 
psychosocial measures raises the possibility that a patient reporting difficulty with 
cognitive functioning may be experiencing psychological distress rather than impaired 
cognitive functioning.  The limited criterion validity of the FACT-Cog and EORTC-CF 
also suggest that patients’ cognitive complaints are more likely to be related to deficits in 
attention, than to deficits in memory, executive functioning, and motor coordination.   
Future Directions 
 Future research should seek to refine the FACT-Cog through item reduction as 
well as to factor analyze the FACT-Cog to provide support for the domain scores.  In 
addition, more research looking at the relationship of cognitive complaints to cognitive 
performance is needed.  Research utilizing a longitudinal design is important to 
determine the temporal stability of cognitive complaints as well as to examine how 
changes in cognitive performance relate to cognitive complaints.  The small effects sizes 
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found in this study suggest the need for research with larger sample sizes to have the 
ability to detect significant difference for small effect sizes.  Additionally, research 
should be conducted with other clinical populations with high rates of impairment where 
detection of relationships between objective and subjective aspects of cognitive 
functioning may be more likely.  Future research should include more demanding 
neuropsychological tasks such as the CPT-II since evidence suggests a stronger 
relationship between cognitive complaints and tasks requiring sustained effort.  Finally, 
neuropsychological tasks that have greater ecological validity, such as memory tasks that 
requires recall over several days, should be used to assess the relationship between 
cognitive performance and cognitive complaints. 
 In conclusion, the present study provides information about the validity and 
reliability of a new measure to assess cognitive complaint in cancer patients, the FACT-
Cog.  Results demonstrated the internal consistency reliability of the FACT-Cog.  The 
concurrent validity of the FACT-Cog was supported by significant relationship to the 
EORTC-CF.  The convergent validity of the FACT-Cog was supported by the significant 
relationships to measures of depression, fatigue, anxiety, mental well-being, physical 
well-being, and neuroticism demonstrating the convergent validity of the measure.  The 
divergent validity of the FACT-Cog was supported by the lack of significant relationship 
with a measure of extroversion.  The criterion validity of the FACT-Cog was generally 
not supported based on the limited number of significant correlations with 
neuropsychological test scores.  The FACT-cog did not demonstrate superior 
psychometric properties than the EORTC-CF, a commonly used measure of cognitive 
complaints.   Future research is needed to reduce the number of items in the FACT-Cog 
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and to factor analyze the FACT-Cog to provide support for the domain scores.  
Additional research should also utilize a longitudinal design, be conducted with other 
clinical populations, and include demanding neuropsychological tasks that require 
sustained effort. 
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Table 1 
 Demographic Characteristics of Sample (N = 82) 
________________________________________________________________ 
Variable                             _____ 
Mean age (SD) 52.91    (12.03) 
Mean education (SD) 13.76    (2.30) 
Estimated IQ (SD) 98.5 (15.30) 
 
Gender 
  Male 42       (51.2%) 
  Female 40  (48.8%) 
 
Ethnicity 
  White/Caucasian 70  (85.4%) 
  Black/African American 7   (8.5%) 
  Latino/Hispanic 4  (4.9%) 
  Other        1  (1.2%) 
 
Marital Status 
  Single, never married     4  (4.9%)  
  Married       65  (79.3%) 
  Divorced 9  (11.0%) 
  Widowed       3  (3.7%) 
  Separated  1  (1.2%) 
 
Employment status 
  Paid full-time employment     23  (28.1%)    
  Paid part-time employment      5  (6.1%) 
  On leave with pay       7  (8.5%) 
  On leave without pay                                       8  (9.8%) 
  Not employed – disabled                           17  (20.7%) 
  Not employed – retired     11  (13.4%) 
  Not employed – Seeking work                          2  (2.4%) 
  Supported by others      9  (11.0%) 
 
Total household income* 
  Less than $ 10,000 4  (5.0%)   
  $10,000 - $19,999      7  (8.8%) 
  $20,000 - $ 39,999 16  (20.0%) 
  $40,000 - $59,999 21  (26.3%) 
  $60,000 - $100,000 18  (22.5%) 
  Greater than $100,000  12  (15.0%) 
* Data missing for 4 participants
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 Table 2  
 
Clinical Characteristics of Sample (N = 82) 
 
Variable                         
 
Evaluation 
  Six month follow-up 56 (68.3%) 
  Twelve month follow-up 26 (31.7%) 
 
BMT Type 
Autologous 70 (85.4%) 
Allogeneic 12 (14.6%) 
 
Diagnosis 
  Multiple Myeloma 59  (72.0%) 
  Non Hodgkins Lymphoma 5  (6.1%) 
  Acute Lymphocytic Leukemia 2  (2.4%) 
  Hodgkins Lymphoma 1  (1.2%) 
  Acute Myelogenous Leukemia 4  (4.9%) 
  Breast Cancer 4  (4.9%) 
  Testicular Cancer 1  (1.2%) 
  Aplastic Anemia 1  (1.2%) 
  Myelodysplasia 1  (1.2%) 
  Chronic Myelogenous Leukemia 3  (3.7%) 
  Amyloidosis 1  (1.2%) 
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Table 3 
 
Correlational Analyses of FACT-Cog and EORTC-CF with Demographic and Clinical 
Variables 
 
 
 FACT-Cog EORTC-CF 
 Total Cognitive IOF QOL  
 
 
Gender .31** .30** .32** .26* .22* 
Age  .03 .07 .04 -.03 .09 
Estimated IQ (NART) .18 .15 .13 .22* .10 
Years of Education -.02 -.03 -.03 .01 -.14 
Race (White/Caucasian or -.13 -.17 -.12 -.09 -.22* 
   All Others) 
Marital Status .15 .17 .15 .11 .08 
Time Since Transplant  .03 .01 .06 .02 .08 
 (6month or 12 month) 
Type of Transplant -.07 -.08 -.07 -.05 -.27** 
         
* p < .05 
**p < .01 
 
IOF = Interference of Functioning 
QOL = Quality of Life
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Table 4 
 
Correlational Analyses of FACT-Cog and EORTC-CF with Psychosocial Variables 
         
 
 FACT-Cog EORTC-CF 
 Total Cognitive IOF QOL  
 
 
Depression (CES-D) .50**** .45**** .44**** .52**** .44**** 
Fatigue (FSI) .53**** .45**** .49**** .58**** .44**** 
Anxiety (STAI) .36*** .33** .31** .39*** .35*** 
Mental Wellbeing (SF-36) -.51**** -.46**** -.50**** -.50**** -.48**** 
Physical Wellbeing (SF-36) -.29** -.27* -.25* -.32** -.31*** 
Extroversion (NEO) -.20 -.18 -.25* -.14 -.30** 
Neuroticism (NEO) .23* .29** .21* .13 .14 
         
* p < .05 
**p < .01 
***p < .001 
**** p < .0001 
   
IOF = Interference of Functioning 
QOL = Quality of Life 
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Table 5 
 
 Regression Analysis of the FACT-Cog Total Score 
 
 
 β R2 change Cumulative R2 p value Uniqueness  
     Index 
 
Demographic variables 
 Gender .201 .094 .094 .005 .037 
 
Psychosocial variables 
 Fatigue (FSI) .265 .257 .357 .0001 .025 
 Mental Well-being -.254 .046 .373 .020 .018 
  (SF-36) 
 Neuroticism (NEO) .118 .007 .380 .362 .011 
 Anxiety (STAI) -.163 .003 .383 .557 .008 
 Depression (CES-D) .150 .005 .389 .432 .005 
 Physical Well-being -.050 .002 .389 .667 .002 
  (SF-36) 
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Table 6 
 
 Regression Analysis of the FACT-Cog Cognitive Domain  
 
 
 β R2 change Cumulative R2 p value Uniqueness  
     Index 
 
Demographic variables 
 Gender .205 .091 .094 .006 .039 
 
Psychosocial variables 
 Mental Well-being -.225 .183 .274 .0001 .014 
  (SF-36) 
 Fatigue (FSI) .169 .023 .298 .111 .010 
 Neuroticism (NEO) .219 .027 .325 .082 .036 
 Anxiety (STAI) -.229 .006 .331 .425 .016 
 Depression (CES-D) .208 .010 .340 .295 .009 
 Physical Well-being -.068 .003 .343 .575 .003 
  (SF-36) 
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Table 7 
 
 Regression Analysis of the FACT-Cog Interference of Functioning 
 
 
 β R2 change Cumulative R2 p value Uniqueness  
     Index 
 
Demographic variables 
 Gender .226 .100 .100 .004 .047 
 
Psychosocial variables 
 Mental Well-being -.357 .222 .322 .0001 .037 
  (SF-36) 
 Fatigue (FSI) .239 .029 .351 .065 .021 
 Extroversion (NEO) -.158 .016 .367 .166 .021 
 Anxiety (STAI) -.181 .012 .379 .232 .011 
 Physical Well-being -.029 .001 .379 .786 .001 
  (SF-36) 
 Depression (CES-D) .047 .000 .380 .819 .001 
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Table 8 
 
 Regression Analysis of the FACT-Cog Quality of Life Domain  
 
 
 β R2 change Cumulative R2 p value Uniqueness  
     Index 
 
Demographic variables 
 Gender .127   .042 .015 
 IQ (NART) .072 .099 .099 .087 .004 
 
Psychosocial variables 
 Fatigue (FSI) .317 .257 .356 .0001 .033 
 Mental Well-being -.173 .027 .383 .07 .008 
  (SF-36) 
 Depression (CES-D) .138 .005 .389 .43 .004 
 Physical Well-being -.042 .001 .389 .73 .001 
  (SF-36) 
 Anxiety (STAI) -.033 .000 .390 .83 .000 
 
  65
Table 9 
 
Correlational Analyses of FACT-Cog and EORTC-CF with Neuropsychological Test 
Performance (Continuous Measures) 
         
 
 FACT-Cog EORTC-CF 
 Total Cognitive IOF QOL  
 
 
Total Neuropsychological  .06 .07 .07 .05 .11 
 Performance 
Memory Domain .11 .11 .10 .08 .05 
Executive Functioning -.05 -.12 -.02 .00 -.03 
 Domain 
Motor Domain -.18 -.16 -.17 -.17 -.11 
Attention Domain .08 .11 .07 .04 .18 
 
 
IOF = Interference of Functioning 
QOL = Quality of Life 
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Table 10 
 
Correlation of FACT-Cog and EORTC-CF with Neuropsychological Test Scores 
(Continuous Measures) 
 
 FACT-Cog EORTC-CF 
 Total Cognitive IOF QOL  
Memory Domain   
 Logical Memory   
  Immediate .07 .08 .08 .05 -.03  
 Delayed .09 .10 .09 .06 .04 
 Visual Reproduction  
  Immediate -.19 -.20 -.18 -.16 -.09 
  Delayed -.11 -.12 -.09 -.10 -.08 
  Recall .08 .04 .05 .13 -.03 
 CVLT 
  Total .15 .12 .15 .17 .10 
  Short Delay Free .14 .16 .14 .10 .15 
  Short Delay Cued .13 .16 .12 .10 .13 
  Long Delay Free .15 .16 .14 .11 .13 
  Long Delay Cued .15 .18 .16 .10 .09 
  Recognition .13 .16 .12 .09 .01 
  Discrimination .13 .18 .11 .08 .00 
 
Executive Functioning Domain 
 Digit Symbol -.10 -.06 -.09 -.12 -.06 
 Trails A .03 -.01 .06 .05 .02 
 Trails B -.01 -.09 .00 .07 .08 
 COWA .03 -.05 .05 .10 -.10 
 Stroop -.11 -.16 -.06 -.09 -.02 
 
Motor Domain 
 Grooved Pegs 
  Dominant -.17 -.16 -.17 -.16 -.16 
  Non-dominant -.15 -.13 -.15 -.15 -.04 
 
Attention Domain 
 CPT-II Subscales  
  Inattention .01 .04 .02 -.03 .17  
  Impulsivity .12 .15 .12 .07 .23* 
  Vigilance .18 .17 .14 .21* .02  
 
*p<.05 
IOF = Interference of Functioning; QOL = Quality of Life
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Table 11 
 
Correlational Analyses of FACT-Cog and EORTC-CF with Neuropsychological Test 
Performance (Impairment Classification) 
         
 
 FACT-Cog EORTC-CF 
 Total Cognitive IOF QOL  
 
 
Total Neuropsychological  .01 .04 .03 -.05 .06 
 Performance 
Memory Domain -.15 -.18 -.16 -.08 -.16 
Executive Functioning .03 .06 .00 .02 .12 
 Domain 
Motor Domain .11 .06 .13 .12 .03 
Attention Domain .08 .02 .04 .16 .10 
 
 
IOF = Interference of Functioning 
QOL = Quality of Life 
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Table 12 
 
Correlation of FACT-Cog and EORTC-CF with Neuropsychological Test Scores 
(Impairment Classification) 
 
  FACT-Cog  EORTC-CF 
 Total Cognitive IOF QOL  
Memory Domain   
 Logical Memory   
  Immediate -.10 -.09 -.11 -.10 -.12 
 Delayed -.05 -.11 -.07 .03 -.12 
 Visual Reproduction  
  Immediate .15 .15 .14 .12 .13 
  Delayed .16 .14 .13 .19 .26* 
  Recall -.10 -.09 -.11 -.10 -.12 
 CVLT  
  Total -.14 -.18 -.12 -.10 -.15 
  Short Delay Free -.14 -.18 -.12 -.10 -.15 
  Short Delay Cued -.18 -.22* -.18 -.12 -.15 
  Long Delay Free -.19 -.22* -.16 -.18 -.15 
  Long Delay Cued -.19 -.21 -.16 -.17 -.15 
  Recognition -.16 -.16 -.14 -.15 .04 
  Discrimination -.14 -.15 -.13 -.11 -.06 
 
Executive Functioning Domain 
 Digit Symbol .07 .07 .03 .09 .07 
 Trails A .08 .08 .02 .13 .18 
 Trails B -.04 -.04 -.05 -.01 -.10 
 COWA -.01 .04 -.01 -.06 .18 
 Stroop .01 .03 -.03 .02 -.10 
 
Motor Domain 
 Grooved Pegs 
  Dominant .12 .09 .14 .11 .14 
  Non-dominant .14 .07 .17 .15 .08 
 
Attention Domain 
 CPT-II Subscales  
  Inattention .16 .14 .13 .19 .26* 
  Impulsivity .28** .23* .24* .33** .30** 
  Vigilance .22* .18 .16 .29** .20 
 
*p<.05, **p<.01 
IOF = Interference of Functioning; QOL = Quality of Life 
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 Table 13 
 
 Regression Analysis of the EORTC-CF Score 
 
 
 β R2 change Cumulative R2 p value Uniqueness  
     Index 
 
Demographic variables 
 Gender .152   .016 .021 
 Race (White or other) -.137   .150 .016 
 Transplant (auto/allo) -.260 .160 .160 .028 .057 
 
Psychosocial variables 
 Mental Well-being -.284 .207 .367 .0001 .023 
  (SF-36) 
 Fatigue (FSI) .198 .029 .396 .060 .014 
 Extroversion (NEO) -.193 .034 .430 .039 .031 
 Physical Well-being -.078 .003 .433 .528 .004 
  (SF-36) 
 Anxiety (STAI) -.059 .001 .434 .728 .001 
 Depression (CES-D) .032 .000 .434 .823 .000 
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale 
 
Below is a list of statements that other people with your condition have said are 
important. By circling one (1) number per line, please indicate how often each of 
the following has occurred during the past 7 days. 
 
 
 
Never About 
once a 
week 
Two to 
three 
times a 
week 
Nearly 
every 
day 
Several 
times  
a day 
I have had trouble forming thoughts .... 0 1 2 3 4 
My thinking has been unclear .............. 0 1 2 3 4 
My thinking has been slow .................. 0 1 2 3 4 
My thinking has been foggy................. 0 1 2 3 4 
I have had trouble adding or 
subtracting numbers in my head...........
0 1 2 3 4 
I have made mistakes when writing 
down phone numbers...........................
0 1 2 3 4 
I have had trouble concentrating .......... 0 1 2 3 4 
I have had trouble remembering the 
name of a familiar person ....................
0 1 2 3 4 
I have had trouble finding my way to 
a familiar place ....................................
0 1 2 3 4 
I have had trouble remembering 
where I put things, like my keys or 
my wallet.............................................
 
0 
 
1 
 
2 
 
3 
 
4 
I have had trouble remembering 
whether I did things I was supposed 
to do, like taking a medicine or 
buying something I needed ..................
 
0 
 
1 
 
2 
 
3 
 
4 
I have had trouble remembering new 
information, like phone numbers or 
simple instructions ..............................
0 1 2 3 4 
I have had trouble recalling the name 
of an object while talking to someone 
0 1 2 3 4 
Words I wanted to use have seemed 
to be on the “tip of my tongue” ............
0 1 2 3 4 
I have had trouble finding the right 
word(s) to express myself ....................
0 1 2 3 4 
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale (Continued) 
 
By circling one (1) number per line, please indicate how often each statement  
has occurred during the past 7 days. 
 
 
 
Never About 
once a 
week 
Two to 
three 
times a 
week 
Nearly 
every 
day 
Several 
times  
a day 
I have used the wrong word when I 
referred to an object .................................
0 1 2 3 4 
I have had trouble speaking fluently......... 0 1 2 3 4 
I have had trouble saying what I mean in 
conversations with others.........................
0 1 2 3 4 
I have needed to keep a written list so I 
would not forget things ............................
0 1 2 3 4 
I have walked into a room and forgotten 
what I meant to get or do there.................
0 1 2 3 4 
I have needed medical instructions 
repeated because I could not keep them 
straight ....................................................
0 1 2 3 4 
I have forgotten or accidentally missed 
medical appointments ..............................
0 1 2 3 4 
I have had to work really hard to pay 
attention or else I would forget what I 
was doing ................................................
0 1 2 3 4 
I have had to work really hard to pay 
attention or I would make a mistake.........
0 1 2 3 4 
I have forgotten names of people soon 
after being introduced..............................
0 1 2 3 4 
My reactions in everyday situations 
have been slow ........................................
0 1 2 3 4 
Other people have noticed that I had 
problems remembering information .........
 
0 
 
1 
 
2 
 
3 
 
4 
Other people have noticed that I had 
problems speaking clearly........................
 
0 
 
1 
 
2 
 
3 
 
4 
Other people have noticed that I had 
problems thinking clearly ........................
0 1 2 3 4 
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale (Continued) 
 
By circling one (1) number per line, please indicate how often each statement 
has occurred during the past 7 days. 
 
 
 
Never About 
once a 
week 
Two to 
three 
times a 
week 
Nearly 
every 
day 
Several 
times  
a day 
It has seemed like my brain was not 
working as well as usual ....................
0 1 2 3 4 
I have had to work harder than usual 
to remember things .............................
0 1 2 3 4 
I have had to work harder than usual 
to keep track of what I was doing........
0 1 2 3 4 
My thinking has been slower than 
usual ...................................................
0 1 2 3 4 
I have had to work harder than usual 
to express myself clearly.....................
0 1 2 3 4 
I have had more problems conversing 
with others ..........................................
0 1 2 3 4 
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale (Continued) 
 
Please answer the remaining questions with regard to all the above concerns  
that you have identified. 
 
 
 
 
Never About 
once a 
week 
Two to 
three 
times a 
week 
Nearly 
every 
day 
Several 
times  
a day 
I have hidden these problems so 
others would not notice .......................
0 1 2 3 4 
I have been upset about these 
problems.............................................
0 1 2 3 4 
I have told others about these 
problems.............................................
0 1 2 3 4 
These problems have interfered with 
my ability to work...............................
0 1 2 3 4 
These problems have interfered with 
my ability to do things I enjoy.............
0 1 2 3 4 
I have tried to do things (like writing 
lists or keeping a calendar) so these 
problems would not interfere ..............
 
0 
 
1 
 
2 
 
3 
 
4 
These problems have been frustrating 
for me .................................................
0 1 2 3 4 
These problems have interfered with 
the quality of my life...........................
0 1 2 3 4 
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale (Continued) 
 
 
Please answer the remaining questions with regard to all the above concerns 
that you have identified. 
 
 Not  
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
I have hidden these problems so 
others would not notice ....................
0 1 2 3 4 
I have been upset about these 
problems..........................................
0 1 2 3 4 
I have told others about these 
problems..........................................
0 1 2 3 4 
These problems have interfered 
with my ability to work....................
0 1 2 3 4 
These problems have interfered 
with my ability to do things I enjoy..
0 1 2 3 4 
I have tried to do things (like 
writing lists or keeping a calendar) 
so these problems would not 
interfere ...........................................
 
0 
 
1 
 
2 
 
3 
 
4 
These problems have been 
frustrating for me .............................
0 1 2 3 4 
These problems have interfered 
with the quality of my life ................
0 1 2 3 4 
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Appendix B: EORTC QLQ-C30 Cognitive Functioning Scale 
 
 
Directions:  For each item below, please check the ONE box. 
During the past week: 
 Not at  A    Quite Very 
   all little     a bit much 
 
1. Have you had difficulty in concentrating   
 on things, like reading a newspaper or                          
 watching television? 
 
 
2. Have you had difficulty remembering                     
things?       
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Appendix C: Center for Epidemiological Studies – Depression  
 
For each statement below, make an “X” in the box which best describes how often you 
felt or behaved this way-- DURING THE PAST WEEK, INCLUDING TODAY. 
 
Rarely or     Some or  Occasionally Most or 
None of       a little  or a moderate all of 
of the time   of the time amount of the the time 
      (< 1 day)      (1-2 days) (3-4 days)         (5-7 days) 
                                                                                                      
DURING THE PAST WEEK: 
                                                                
1. I was bothered by things that 
usually don't bother me............................ r   r   r    r  
 
2. I did not feel like eating; my 
appetite was poor .................................... r   r   r    r  
 
3. I felt that I could not shake off the 
blues even with help from my  
family or friends ....................................... r   r   r    r  
 
4. I felt that I was just as good as 
other people............................................. r   r   r    r  
 
5. I had trouble keeping my mind on  
what I was doing...................................... r   r   r    r  
 
6. I felt depressed ........................................ r   r   r    r  
 
7. I felt that everything I did was  
an effort ................................................... r   r   r    r  
 
8. I felt hopeful about the future ................... r   r   r    r  
 
9. I thought my life had been a failure .......... r   r   r    r  
 
10. I felt fearful............................................... r   r   r    r  
 
11. My sleep was restless.............................. r   r   r    r  
 
12. I was happy ............................................. r   r   r    r  
 
13. I talked less than usual ............................ r   r   r    r  
 
14. I felt lonely ............................................... r              r   r    r  
 
15. People were unfriendly ............................ r   r   r    r  
 
16. I enjoyed life ............................................ r   r   r    r  
 
17. I had crying spells .................................... r   r   r    r  
 
18. I felt sad................................................... r   r   r    r  
 
19. I felt that people disliked me..................... r   r   r    r  
 
20. I could not “get going” .............................. r   r   r    r  
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Appendix D: State-Trait Anxiety Inventory 
 
DIRECTIONS:  A number of statements which people have used to describe 
themselves are given below.  Read each statement and then check the 
appropriate box to the right of the statement to indicate how you feel right now, 
that is, at this moment.  There are no right or wrong answers.  Do not spend too 
much time on any one statement but give the answer which seems to describe 
your present feelings best. 
 
 NOT  SOMEWHAT    MODERATELY      VERY 
 AT ALL    SO MUCH SO   
 
1. I feel calm.. ............................     
 
2. I feel secure............................     
 
3. I am tense. .............................     
 
4. I feel strained..........................     
 
5. I feel at ease...........................     
 
6. I feel upset..............................     
 
7. I am presently worrying 
over possible misfortunes.......     
 
8. I feel satisfied. ........................      
 
9. I feel frightened.. ...................     
 
10. I feel comfortable....................     
 
11. I feel self-confident. ................     
 
12. I feel nervous..........................     
 
13. I am jittery...............................     
 
14. I feel indecisive.......................     
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Appendix D: State-Trait Anxiety Inventory (Continued) 
 
 NOT  SOMEWHAT    MODERATELY      VERY 
 AT ALL    SO MUCH SO   
 
 
15. I am relaxed. ..........................     
 
16. I feel content...........................     
 
17. I am worried. ..........................     
           
18. I feel confused........................     
 
19. I feel steady............................     
 
20. I feel pleasant.........................     
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Appendix E: Fatigue Symptom Inventory 
 
PART I. For each of the following, circle the one number that best indicates how that item applies to you.  
 
1. Rate your level of fatigue on the day you felt most fatigued during the past week. 
     
0 1 2 3 4 5 6  7 8 9 10 
Not at all         As fatigued   
fatigued         as I could be 
 
2. Rate your level of fatigue on the day you felt least fatigued during the past week. 
 
0 1 2 3 4 5 6  7 8 9 10 
Not at all         As fatigued   
fatigued         as I could be 
 
3. Rate your level of fatigue on the average in the last week. 
 
0 1 2 3 4 5 6  7 8 9 10 
Not at all         As fatigued   
fatigued         as I could be 
 
4. Rate your level of fatigue right now. 
 
0 1 2 3 4 5 6  7 8 9 10 
Not at all         As fatigued   
fatigued         as I could be 
 
5. Rate how much, in the past week, fatigue interfered with your general level of activity: 
 
0 1 2 3 4 5 6  7 8 9 10 
No          Extreme    
interference         interference 
 
6. Rate how much, in the past week, fatigue interfered with your ability to bathe and dress 
 yourself: 
 
0 1 2 3 4 5 6  7 8 9 10 
No           Extreme     
interference          interference 
 
7. Rate how much, in the past week, fatigue interfered with your normal work activity       (includes 
both work outside the home and housework): 
 
0 1 2 3 4 5 6  7 8 9 10 
No          Extreme  
         interference             interference
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Appendix E: Fatigue Symptom Inventory (Continued) 
 
8.  Rate how much, in the past week, fatigue interfered with your ability to concentrate: 
 
0 1 2 3 4 5 6  7 8 9 10 
No          Extreme  
interference                       interference 
 
9. Rate how much, in the past week, fatigue interfered with your relations with other people: 
 
0 1 2 3 4 5 6  7 8 9 10 
No          Extreme        
interference             interference 
 
10. Rate how much, in the past week, fatigue interfered with your enjoyment of life: 
 
0 1 2 3 4 5 6  7 8 9 10 
No          Extreme    
interference             interference 
 
11. Rate how much, in the past week, fatigue interfered with your mood: 
 
0 1 2 3 4 5 6  7 8 9 10 
No          Extreme   
  interference         interference 
 
12. Indicate how many days, in the past week, you felt fatigued for any part of the day: 
 
0 1 2 3 4 5 6 7 
   Days               Days 
 
13. Rate how much of the day, on average, you felt fatigued in the past week: 
 
0 1 2 3 4 5 6 7 8 9 10 
None of           The entire  
the day              day  
 
14. Indicate which of the following best describes the daily pattern of your fatigue in the past        
 week: 
 
0     1  2   3  4 
Not at all       Worse in     Worse in the  Worse in  No consistent daily  
       fatigued                     the morning                    afternoon       the evening      pattern of fatigue 
 
  90
Appendix F: Medical Outcome SF-36 Health Survey 
 
INSTRUCTIONS:  This survey asks for your views about your health.  This information will 
help keep track of how you feel and how well you are able to do your usual activities.  Answer 
every question by marking the answer as indicated.  If you are unsure about how to answer a 
question, please give the best answer you can. 
 
1. In general, would you say your health is (check one): 
             Excellent r  Very good r     Good r      Fair r      Poor r 
 
2. Compared to one year ago, how would you rate your health in general now?  (check one) 
Much better now than one year ago  r 
Somewhat better now than one year ago r 
About the same as one year ago  r 
Somewhat worse now than one year ago r 
Much worse than one year ago               r 
  
3. The following items are about activities you might do during a typical day.  Does your 
health now limit you in these activities?  If so, how much?  (check appropriate answer) 
 
 
       Yes,  
Limited a lot 
        Yes,  
Limited a little 
     No, Not 
limited at all 
 
a.  Vigorous activities, such as 
running, lifting heavy objects,       
participating in strenuous sports 
 
 
r 
 
 
r 
 
 
r 
 
b.  Moderate activities, such as 
moving a table, pushing a           
vacuum cleaner, bowling, or 
playing golf 
 
 
r 
 
 
r 
 
 
r 
 
c.  Lifting or carrying groceries     r          r r 
 
 
d.  Climbing several flights of 
stairs 
 
r 
 
r 
 
r 
 
e.  Climbing one flight of stairs 
 
r 
 
r 
 
r 
 
f.   Bending, kneeling or stooping 
 
r 
 
r 
 
r 
 
g.  Walking more than a mile 
 
r 
 
r 
 
r 
 
h.  Walking several blocks 
 
r 
 
r 
 
r 
 
i.   Walking one block 
 
r 
 
r 
 
r 
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Appendix F: Medical Outcome SF-36 Health Survey (Continued) 
 
4. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health?  (check yes or no for 
each) 
 
 
       Yes          No 
     a.  Cut down the amount of time you spent on work or  
           other activities     r      r 
     b.  Accomplished less than you would like        r          r 
     c.  Were limited in the kind of work or other activities        r          r 
     d.  Had difficulty performing the work or other activities (for  
example, it took extra effort)        r          r 
 
 
 
 
 
5. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result any emotional problems (such as feeling 
depressed or  anxious)?  (check yes or no for each) 
 
 
 
Yes 
 
No 
 
     a.  Cut down the amount of time you spent on work or other     
activities 
 
r 
 
r 
 
     b.  Accomplished less than you would like 
 
r 
 
r 
 
     c.  Didn't do work or other activities as carefully as usual 
 
r 
 
r 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups?  
(check one) 
Not at all  r 
Slightly                r 
Moderately  r 
Quite a bit  r 
Extremely  r 
 
 
7. How much bodily pain have you had during the past 4 weeks?  (check one) 
None   r 
Very mild  r 
Mild   r 
Moderate  r 
Severe   r 
Very severe  r 
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Appendix F: Medical Outcome SF-36 Health Survey (Continued) 
 
8. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)?  (check one) 
 
Not at all  r 
A little bit  r 
Moderately  r 
Quite a bit  r 
Extremely  r 
 
 
9. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling.  (check appropriate answer). 
 
 
How much of the time 
during the past 4 weeks: 
 
All of  
the 
time 
 
Most 
of the 
time 
 
A good 
bit of 
the time 
 
Some 
of the 
time 
 
A little 
of the 
time 
 
 None 
of  the 
time 
 
a.  Did you feel full of pep? 
 
r 
 
r 
 
r 
 
r 
 
r 
 
r 
 
b.  Have you been a very 
nervous person? 
 
 
r 
 
 
r 
 
 
r 
 
 
r 
 
 
r 
 
 
r 
 
c.  Have you felt so down in the 
dumps that nothing could cheer 
you up? 
 
 
r 
 
 
r 
 
 
r 
 
 
r 
 
 
r 
 
 
r 
 
d.  Have you felt calm and 
peaceful? 
 
r 
 
r 
 
r 
 
r 
 
r 
 
r 
 
e.  Did you have a lot of energy? 
 
r 
 
r 
 
r 
 
r 
 
r 
 
r 
 
f.  Have you felt downhearted 
and blue? 
 
r 
 
r 
 
r 
 
r 
 
r 
 
r 
 
g.  Did you feel worn out? 
 
r 
 
r 
 
r 
 
r 
 
r 
 
r 
 
h.  Have you been a happy 
person? 
 
r 
 
r 
 
r 
 
r 
 
r 
 
r 
 
i.  Did you feel tired? 
 
r 
 
r 
 
r 
 
r 
 
r 
 
r 
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Appendix F: Medical Outcome SF-36 Health Survey (Continued) 
 
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)?  (check one) 
 
All of the time      r 
Most of the time   r 
Some of the time r 
A little of the time r 
None of the time  r 
 
 
11. How TRUE or FALSE is each of the following statements for you? (check 
appropriate answer) 
 
 
 
Defi-       
nitely       
true 
Mostly   
true 
Don't     
know 
Mostly 
false 
Defi-       
nitely       
false 
 
a.  I seem to get sick a little easier       
than other people 
 
 
r 
 
 
r 
 
 
r 
 
 
r 
 
 
r 
 
b.  I am as healthy as anybody I          
know 
 
r 
 
r 
 
r 
 
r 
 
r 
 
c.  I expect my health to get worse 
 
r 
 
r 
 
r 
 
r 
 
r 
 
d.  My health is excellent 
 
r 
 
r 
 
r 
 
r 
 
r 
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Appendix G: NEO – Five-Factor Inventory 
 
Instructions:  This questionnaire contains 60 statements.  Read each statement carefully.  
For each statement, check the box that goes with the response that best represents your 
opinion.  Check only one box for each statement. 
            Strongly                  Strongly  
       Disagree    Disagree  Neutral    Agree    Agree 
 
1.     I am not a worrier ................................................. r....  r  r    r  r 
 
2. I like to have a lot of people around me  .............. r  r  r   r  r 
    
3. I don’t like to waste my time daydreaming ........... r  r  r   r  r 
 
4. I try to be courteous to everyone I meet ................ r  r  r   r  r 
 
5. I keep my belongings clean and neat ....................r  r  r   r  r 
  
6. I often feel inferior to others.................................r  r  r   r  r 
 
7. I laugh easily ................................................... r  r  r   r  r 
 
8.  Once I find the right way to do something,  
  I stick to it ................................................... r  r  r   r  r 
  
9. I often get into arguments with my family 
       and co-workers ...................................................r  r  r   r  r 
  
10. I’m pretty good about pacing myself 
       so as to get things done on time ............................. r  r  r   r  r 
  
11. When I am under a great deal of stress, 
        sometimes I feel like I’m going to pieces .............. r  r  r   r  r 
  
12. I don’t consider myself especially 
        “light-hearted.” ...................................................r  r  r   r  r 
 
13. I am intrigued by the patterns I find in  
       art and nature ...................................................r  r  r   r  r 
 
14.  Some people think I’m selfish and egotistical ........ r  r  r   r  r 
 
15.  I am not a very methodical person .........................r  r  r   r  r 
  
16.  I rarely feel lonely or blue .....................................r  r  r   r  r 
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Appendix G: NEO – Five-Factor Inventory (Continued) 
 
            Strongly                  Strongly  
       Disagree    Disagree  Neutral    Agree    Agree 
 
17.  I really enjoy talking to people ..............................r  r  r   r  r 
 
18.  I believe letting students hear controversial 
       speakers can only confuse and mislead them ......... r  r  r   r  r 
  
19.  I would rather cooperate with others than ................. 
       compete with them ................................................ r  r  r   r  r 
 
20.  I try to perform all the tasks assigned to  
       me conscientiously ................................................ r  r  r   r  r 
 
21.  I often feel tense and jittery ................................... r  r  r   r  r 
 
22.  I like to be where the action is ............................... r  r  r   r  r 
 
23.  Poetry has little or no effect on me ........................ r  r  r   r  r 
 
24.  I tend to be cynical and skeptical of others’ 
       intentions ................................................... r  r  r   r  r 
 
25.  I have a clear set of goals and work toward 
       them in an orderly fashion ..................................... r  r  r   r  r 
 
26.  Sometimes I feel completely worthless .................. r  r  r   r  r 
 
27.  I usually prefer to do things alone.......................... r  r  r   r  r 
 
28.  I often try new and foreign foods ........................... r  r  r   r  r 
 
29.  I believe that most people will take  
      advantage of you if you let them............................. r  r  r   r  r 
 
30. I waste a lot of time before settling down  
      to work ................................................... r  r  r   r  r 
 
31. I rarely feel fearful or anxious ................................r  r  r   r  r 
 
32. I often feel as if I’m bursting with energy ............... r  r  r   r  r 
 
33. I seldom notice the moods or feelings 
      that different environments produce ....................... r  r  r   r  r 
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Appendix G: NEO – Five-Factor Inventory (Continued) 
 
            Strongly                  Strongly  
       Disagree    Disagree  Neutral    Agree    Agree 
 
34.  Most people I know like me .................................. r  r  r   r  r 
 
35.  I work hard to accomplish my goals ......................r  r  r   r  r 
 
36.  I often get angry at the way people treat me........... r  r  r   r  r 
 
37.  I am a cheerful, high-spirited person......................r  r  r   r  r 
 
38.  I believe we should look to our religious...................  
       authorities for decisions on moral issues ................ r  r  r   r  r 
 
39.  Some people think of me as cold and  
       calculating ...................................................r  r  r   r  r 
 
40.  When I make a commitment, I can always 
       be counted on to follow through ............................r  r  r   r  r 
 
41.  Too often, when things go wrong, I get ....................  
       discouraged and feel like giving up........................ r  r  r   r  r 
  
42.  I am not a cheerful optimist ...................................r  r  r   r  r 
 
43.  Sometimes when I am reading poetry ....  
or looking at a work of art, I feel a chill 
       or wave of excitement ...........................................r  r  r   r  r 
 
44.  I’m hard-headed and tough-minded in 
       my attitudes ................................................... r  r  r   r  r 
 
45.  Sometimes I’m not as dependable or 
       reliable as I should be............................................r  r  r   r  r 
 
46.  I am seldom sad or depressed ................................ r  r  r   r  r 
 
47.  My life is fast-paced..............................................r  r  r   r  r 
 
48.  I have little interest in speculating on the  
nature of the universe or the human  
       condition ................................................... r  r  r   r  r 
 
49.  I generally try to be thoughtful and considerate...... r  r  r   r  r 
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Appendix G: NEO – Five-Factor Inventory (Continued) 
 
            Strongly                  Strongly  
       Disagree    Disagree  Neutral    Agree    Agree 
  
50.  I am a productive person who always get the 
       job done ................................................... r  r  r   r  r 
 
51.  I often feel helpless and want someone 
       else to solve my problems ..................................... r  r  r   r  r 
 
52.  I am a very active person.......................................r  r  r   r  r 
 
53.  I have a lot of intellectual curiosity........................r  r  r   r  r 
 
54.  If I don’t like people, I let them know it................. r  r  r   r  r 
 
55.  I never seem to be able to get organized ................r  r  r   r  r 
 
56.  At times I have been so ashamed I just  
       want to hide ................................................... r  r  r   r  r 
 
57.  I would rather go my own way then be a  
       leader of others ................................................... r  r  r    r  r 
 
58.  I often enjoy playing with theories or  
       abstract ideas ................................................... r  r  r   r  r 
 
59.  If necessary, I am willing to manipulate  
       people to get what I want.......................................r  r  r   r  r 
 
60.  I strive for excellence in everything I do ................r  r  r   r  r 
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Appendix H: Background Interview 
 
BACKGROUND INTERVIEW 
 
 
Name:  
MR#:  
Age/DOB: 
Handedness: 
Race: 
Marital Status: 
Referring M.D.:  
Date of Assessment:  
ECOG (neuro only): 
 
Karnofsky (neuro only): 
 
History of Present Illness:  
Diagnosis: 
Diagnosis date: 
BMT type: 
Treatment so far? 
 
 
 
Psychiatric History:  
Have you ever seen a psychiatrist or other mental health professional? YES  NO 
Were you ever hospitalized for mental problems?         YES       NO 
Do you see a psychiatrist or other mental health professional now?       YES       NO 
 
Current Medications:  
 
 
 
Family Medical and Psychiatric History:  
Is there a family history of cancer? 
 
Are there family members with mental problems?  Alcohol?  Drugs? YES  NO 
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Appendix H: Background Interview (Continued) 
 
Social History:  
Who do you live with? 
 
Where do you live? 
 
Do you have any children? 
 
How far did you go in school?   
 
Any learning or attention problems as you were going through school? 
 
Are you currently working? If not, when did you stop? Do you receive SSI or 
disability? 
 
 
 
How have you been sleeping? 
 
 
 
How is your appetite? 
 
 
 
Do you have a history of smoking? Alcohol consumption? Illicit drug use? 
 
 
 
How much caffeine do you typically drink? 
 
 
Do you have any other medical history of which we should be aware? 
 
 
 
Do you have any history of head injury of loss of consciousness? Did this leave 
any lasting effects? 
 
Mental Status (any comments):  
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Appendix H: Background Interview (Continued) 
 
MENTAL STATUS EXAM 
 
Appearance:  (hygiene, dress, eye contact, posture, gait, level of consciousness, 
attentiveness) 
 
Does he/she appear his/her chronological age? 
 
 
 
Attitude: __ Cooperative __ Uncooperative  
 
Activity: __ Normal  __ Psychomotor Retardation (or)  __ Agitation 
  __ Tremor   
 
Mood:  __ Euthymic __ Dysphoric __ Angry __ Anxious __ Apathetic 
 
Affect:  (parameters:  appropriateness, intensity, mobility, range reactivity) 
 __ Incongruent __ Flat  __ Tearful __ Labile 
 __ Appropriate __ Normal __ Full Range 
 
Speech:  (rate, flow, volume, clarity, spontaneity, word finding difficulties) 
 
 
Thought Process: 
 __ Organized  __ Disorganized __ Tangential  __ Loose Association 
 
Level of Consciousness: __ Alert __ Drowsy __ Delirium __ Stupor 
 
Depression: (2 week period) 
__ Depressed Mood  __ Diminished interest/pleasure __ Weight Loss 
__ Insomnia/hyper  __ Psychomotor changes  __ Fatigue/Loss of energy 
__ Worthlessness/guilt  __ Poor concentration/decision making 
__ Thoughts of death/suicidal ideation 
 
Adjustment: (3 months) 
__ Marked Distress  __ Impairment (social/occupational) 
__Depressed   __ Anxiety    __ Mixed  
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Appendix I: National Adult Reading Test 
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Appendix J: Conners’ Continuous Performance Task-II 
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Appendix J: Conners’ Continuous Performance Task-II (Continued) 
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Appendix K: California Verbal Learning Test 
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Appendix K: California Verbal Learning Test (Continued) 
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Appendix K: California Verbal Learning Test (Continued) 
 
 
 
 
  107
Appendix L: Logical Memory 
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Appendix L: Logical Memory (Continued) 
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Appendix L: Logical Memory (Continued) 
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Appendix M: Visual Reproduction 
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Appendix M: Visual Reproduction (Continued) 
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Appendix N: Digit Symbol 
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Appendix O: Trail Making Test A 
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Appendix P: Trail Making Test B 
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Appendix Q: Controlled Oral Word Association 
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Appendix R: Stroop 
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Appendix S: Grooved Pegboard 
 
 
 
 
 
